,Start Date,Start Price,End Date,End Price,Weekly Returns,Bin Label,News,Basics
0,2024-11-03,314.14947509765625,2024-11-10,320.1131896972656,0.018983684749928287,U2,"[{""date"": ""20241103111803"", ""headline"": ""Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market"", ""summary"": ""Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and attractive valuation.""}, {""date"": ""20241103190000"", ""headline"": ""Big Pharma\u2019s Obesity Bonanza Faces New Tests"", ""summary"": ""Big Pharma\u2019s Obesity Bonanza Faces New Tests""}, {""date"": ""20241104043800"", ""headline"": ""Amgen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Amgen Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20241104230335"", ""headline"": ""Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy Right Now?"", ""summary"": ""We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other pharma stocks. Healthcare takes the concept of \u2018defensive\u2019 further than almost any industry, encompassing many companies that provide patient care, engage in [\u2026]""}, {""date"": ""20241105043800"", ""headline"": ""Amgen Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Amgen Inc. stock rises Tuesday, still underperforms market""}, {""date"": ""20241105140012"", ""headline"": ""Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know"", ""summary"": ""Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""20241106003758"", ""headline"": ""Novo Nordisk: A GLP-1 Leader Faces Increasing Competition"", ""summary"": ""Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell.""}, {""date"": ""20241106144013"", ""headline"": ""Are You a Value Investor? This 1 Stock Could Be the Perfect Pick"", ""summary"": ""Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.""}, {""date"": ""20241106163800"", ""headline"": ""Amgen Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Amgen Inc. stock rises Wednesday, still underperforms market""}, {""date"": ""20241107091113"", ""headline"": ""FDA Accepts ABLAs For Prolia\u00ae / Xgeva\u00ae Biosimilars From Organon And Teva"", ""summary"": ""On October 30, 2024, Organon announced the FDA acceptance of its aBLA for HLX14, a proposed biosimilar of Amgen's Prolia\u00ae / Xgeva\u00ae . Organon licensed the commercialization rights for HLX14 in the...""}, {""date"": ""20241107130104"", ""headline"": ""Amgen Insiders Sold US$4.0m Of Shares Suggesting Hesitancy"", ""summary"": ""In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...""}, {""date"": ""20241107163800"", ""headline"": ""Amgen Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Amgen Inc. stock rises Thursday, still underperforms market""}, {""date"": ""20241108070000"", ""headline"": ""TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS"", ""summary"": ""Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE\u00ae (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. The safety profile and tolerability of TEZSPIRE in the trial were consistent with the k""}, {""date"": ""20241108113416"", ""headline"": ""Amgen : Army Veteran Mike Berke Helping Lead the Charge in Research Automation"", ""summary"": ""For 20 years, former Green Beret Mike Berke, a director of Engineering and member of Amgen's Veteran Employee Network , has led the charge for Amgen's Research & Automation Technologies. This team...""}, {""date"": ""20241108134708"", ""headline"": ""AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis"", ""summary"": ""AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) The data showed that Tezspire demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. Also Read: Amgen/AstraZeneca\u2019s Asthma Drug Tezspire Vs. Sanofi/Regeneron\u2019s Blockbuster Dupixent""}, {""date"": ""20241108145247"", ""headline"": ""AstraZeneca and Amgen\u2019s Tezspire succeeds in Phase III nasal polyps trial"", ""summary"": ""A Phase III trial with the companies\u2019 monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its primary endpoint.""}, {""date"": ""20241108210000"", ""headline"": ""AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE"", ""summary"": ""Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.""}, {""date"": ""20241109005709"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of November 10"", ""summary"": ""Stay up to date on dividend activity with our weekly summary for Dividend Champions, Contenders, and Challengers, including ex-dividend and pay dates.""}, {""date"": ""20241110120000"", ""headline"": ""As Trump Readies a Reset of Antitrust Policy, Look to These Sectors for Deals"", ""summary"": ""A change in leadership at the Federal Trade Commission could spark mergers and acquisitions in tech, healthcare and beyond.""}]",{}
1,2024-11-10,320.1131896972656,2024-11-17,279.1051025390625,-0.12810495936448263,D5+,"[{""date"": ""20241110120000"", ""headline"": ""As Trump Readies a Reset of Antitrust Policy, Look to These Sectors for Deals"", ""summary"": ""A change in leadership at the Federal Trade Commission could spark mergers and acquisitions in tech, healthcare and beyond.""}, {""date"": ""20241111103733"", ""headline"": ""AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE"", ""summary"": ""THOUSAND OAKS - Amgen will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024.Peter Griffith, executive vice president and chief financial officer at...""}, {""date"": ""20241111163800"", ""headline"": ""Amgen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Monday when compared to competitors""}, {""date"": ""20241112125800"", ""headline"": ""Dow drops nearly 350 points on losses for 3M, Boeing stocks"", ""summary"": ""Dow drops nearly 350 points on losses for 3M, Boeing stocks""}, {""date"": ""20241112135900"", ""headline"": ""3M, Boeing share losses lead Dow's nearly 200-point drop"", ""summary"": ""3M, Boeing share losses lead Dow's nearly 200-point drop""}, {""date"": ""20241112152600"", ""headline"": ""Dow's 300-point fall led by losses in shares of Amgen, 3M"", ""summary"": ""Dow's 300-point fall led by losses in shares of Amgen, 3M""}, {""date"": ""20241112163800"", ""headline"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20241112213858"", ""headline"": ""Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot"", ""summary"": ""Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral density loss.""}, {""date"": ""20241113052439"", ""headline"": ""Amgen sees no bone safety concerns around experimental obesity drug"", ""summary"": ""Amgen said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, a day after data from an early-stage study dragged its stock 7% lower. ...""}, {""date"": ""20241113063109"", ""headline"": ""Amgen Says No Link Between MariTide, Bone Density Loss"", ""summary"": ""By Colin Kellaher Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more...""}, {""date"": ""20241113091024"", ""headline"": ""Johnson & Johnson: Tracking Well Above The Industry"", ""summary"": ""Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.""}, {""date"": ""20241113100000"", ""headline"": ""AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA"", ""summary"": ""Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.""}, {""date"": ""20241113102439"", ""headline"": ""Amgen dismisses bone density concerns related to its new weight-loss drug"", ""summary"": ""The company's stock slumped 7% on Tuesday after analysts at Cantor Fitzgerald said their review of early-stage data on Amgen's MariTide showed the drug had led to a drop in bone mineral density.  \""The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide,\"" Amgen said, adding that it looks forward to data from its mid-stage study later this year.  Shares of Amgen rose 2% in premarket trade after the company's statement.""}, {""date"": ""20241113111552"", ""headline"": ""Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing"", ""summary"": ""An analyst note raising questions about Amgen\u2019s MariTide triggered a stock sell-off Tuesday. Elsewhere,\u00a0Roche and Novartis struck drug discovery deals.""}, {""date"": ""20241113113100"", ""headline"": ""Dow up 186 points on gains for Home Depot, Goldman Sachs shares"", ""summary"": ""Dow up 186 points on gains for Home Depot, Goldman Sachs shares""}, {""date"": ""20241113132904"", ""headline"": ""Understanding Cardiovascular Risk: The Role of LDL-C, Comorbidities and Early Intervention"", ""summary"": ""or bad cholesterol - is one of the most significant modifiable risk factors.1-5 For someone with established cardiovascular disease , the presence of an additional CV condition, or comorbidity, can...""}, {""date"": ""20241113152805"", ""headline"": ""MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM"", ""summary"": ""NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Moore Law,\u00a0PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: ...""}, {""date"": ""20241113161909"", ""headline"": ""Amgen Inc. (AMGN) UBS Global Healthcare Conference (Transcript)"", ""summary"": ""Amgen Inc. (NASDAQ:AMGN) UBS Global Healthcare Conference November 13, 2024 1:15 PM ETCompany ParticipantsPeter Griffith - CFONarimon Honarpour - SVP,...""}, {""date"": ""20241113163800"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Amgen Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241113165502"", ""headline"": ""Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?"", ""summary"": ""Amgen stock rebounded Wednesday, shaking off \""overdone\"" fears that its monthly weight-loss shot causes excessive bone mineral density loss.""}, {""date"": ""20241113185920"", ""headline"": ""Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density"", ""summary"": ""On Tuesday, a Cantor analyst wrote that additional data from Amgen\u2019s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc (NASDAQ:AMGN) stated the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data, saying, \u201cAmgen does not see an association between the administration of MariTide and bone mineral density (BMD) changes. The Phase 1 study results do not suggest any bone safety concerns or change our conviction i""}, {""date"": ""20241114120200"", ""headline"": ""Dow's 111-point drop led by losses for Salesforce, Cisco stocks"", ""summary"": ""Dow's 111-point drop led by losses for Salesforce, Cisco stocks""}, {""date"": ""20241114133451"", ""headline"": ""Amgen speaks out about bone density concerns with obesity drug"", ""summary"": ""Amgen\u2019s stock fell 7% after an analyst posted a note on MariTide\u2019s influence on bone density which was noticed in a data spreadsheet.""}, {""date"": ""20241114145444"", ""headline"": ""Citi initiates coverage on 5 new biotech stocks"", ""summary"": ""Investing.com -- Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and Vertex (NASDAQ:VRTX).""}, {""date"": ""20241114150700"", ""headline"": ""Dow's 238-point fall led by losses in UnitedHealth, Salesforce shares"", ""summary"": ""Dow's 238-point fall led by losses in UnitedHealth, Salesforce shares""}, {""date"": ""20241114151500"", ""headline"": ""2 Dividend Stocks to Buy Hand Over Fist in November"", ""summary"": ""These companies have solid businesses and excellent dividend growth track records.""}, {""date"": ""20241114163800"", ""headline"": ""Amgen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Thursday when compared to competitors""}, {""date"": ""20241114185300"", ""headline"": ""5 Healthcare Stocks to Buy in a Beaten-Up Sector"", ""summary"": ""It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.  The  Health Care Select Sector SPDR Fund  which owns shares of major U.S. health insurers, medical device makers, and drugmakers, has dropped about 7% since hitting a record high in mid-September.  Investors have been selling healthcare stocks, buying up more economically-sensitive ones instead, as the Federal Reserve has cut interest rates and the market accounts for the positive economic consequences from Republicans winning the White House and both chambers of Congress.""}, {""date"": ""20241114200000"", ""headline"": ""Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate"", ""summary"": ""AMGN says there was no connection between the administration of MariTide and bone mineral density changes.""}, {""date"": ""20241114210000"", ""headline"": ""AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., Nov. 14-19, 2024. New data showcase reduction in disease activity by UPLIZNA\u00ae (inebilizumab-cdon) in Immunoglobulin G4-Related Disease (IgG4-RD) and support shorter infusion times for KRYSTEXXA\u00ae (pegloticase) co-administered with weekly oral methotrexate 15 mg.""}, {""date"": ""20241115094500"", ""headline"": ""Merck, Amgen share losses lead Dow's 168-point drop"", ""summary"": ""Merck, Amgen share losses lead Dow's 168-point drop""}, {""date"": ""20241115095738"", ""headline"": ""How To Invest $100,000 In Large Cap Stocks: A Tax-Efficient Advisor-Less Strategy"", ""summary"": ""This DIY market index strategy blends large-cap stocks and ETFs, plus tax loss harvesting. Read how you can save on fees and manage your own portfolio.""}, {""date"": ""20241115104600"", ""headline"": ""Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop"", ""summary"": ""Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop""}, {""date"": ""20241115105410"", ""headline"": ""A Journey of Courage: Empowering Others with Gastric Cancer"", ""summary"": ""During this Gastric Cancer Awareness Month , watch Essie Graeber's courageous journey through her diagnosis and treatment of gastric cancer. In this powerful video, she opens up about the profound...""}, {""date"": ""20241115123600"", ""headline"": ""Dow falls nearly 400 points on losses for shares of Amgen, Amazon.com Inc."", ""summary"": ""Dow falls nearly 400 points on losses for shares of Amgen, Amazon.com Inc.""}, {""date"": ""20241115134821"", ""headline"": ""RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking."", ""summary"": ""RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.""}, {""date"": ""20241115144700"", ""headline"": ""Amazon.com Inc., Amgen share losses lead Dow's 275-point drop"", ""summary"": ""Amazon.com Inc., Amgen share losses lead Dow's 275-point drop""}, {""date"": ""20241115163800"", ""headline"": ""Amgen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20241116110030"", ""headline"": ""The three-year decline in earnings for Amgen NASDAQ:AMGN) isn't encouraging, but shareholders are still up 50% over that period"", ""summary"": ""Amgen Inc. ( NASDAQ:AMGN ) shareholders might be concerned after seeing the share price drop 13% in the last week. But...""}, {""date"": ""20241116134500"", ""headline"": ""2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious"", ""summary"": ""Its future is bright, but that doesn't mean it'll always be smooth sailing.""}, {""date"": ""20241116140032"", ""headline"": ""The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?"", ""summary"": ""The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded companies.""}]",{}
2,2024-11-17,279.1051025390625,2024-11-24,292.1695556640625,0.04680836360980378,U5,"[{""date"": ""20241118102100"", ""headline"": ""Nike, NVIDIA Corp. share losses lead Dow's 111-point drop"", ""summary"": ""Nike, NVIDIA Corp. share losses lead Dow's 111-point drop""}, {""date"": ""20241118140012"", ""headline"": ""Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""20241118144200"", ""headline"": ""Amgen Sells Off: Keep Calm And Buy The Dip"", ""summary"": ""Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile market. Click here to read more.""}, {""date"": ""20241118144403"", ""headline"": ""Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now?"", ""summary"": ""We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by [\u2026]""}, {""date"": ""20241118163900"", ""headline"": ""Amgen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Monday when compared to competitors""}, {""date"": ""20241119111008"", ""headline"": ""Navigating The Shifting Sands Of Biotechnology Patenting (Video)"", ""summary"": ""Taken from a webinar between Suzanne Renes, Nicole Mastrangelo and David Diamond on 24 September 2024, chaired by Will Arends The world of biotechnology and therapeutic patents has seen a flurry of...""}, {""date"": ""20241119112803"", ""headline"": ""Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)"", ""summary"": ""Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.""}, {""date"": ""20241119205947"", ""headline"": ""Amgen Stock Has High Implied Volatility. An Iron Condor Takes Advantage."", ""summary"": ""With the recent spike in implied volatility, an iron condor on Amgen can use short strikes with a wide profit range.""}, {""date"": ""20241120090800"", ""headline"": ""XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)"", ""summary"": ""We advise selling healthcare stocks due to political uncertainty and unfavorable market conditions, prioritizing low-risk investments. See more on XLV ETF here.""}, {""date"": ""20241120153500"", ""headline"": ""UnitedHealth, Amgen share gains lead Dow's 114-point climb"", ""summary"": ""UnitedHealth, Amgen share gains lead Dow's 114-point climb""}, {""date"": ""20241120160400"", ""headline"": ""SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels"", ""summary"": ""Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.""}, {""date"": ""20241120163911"", ""headline"": ""Amgen Names Howard Chang as Chief Scientific Officer"", ""summary"": ""By Stephen Nakrosis Amgen on Wednesday said Howard Chang will join the company as senior vice president of research, effective Dec. 16. The company said Chang, who will also serve as chief...""}, {""date"": ""20241120210000"", ""headline"": ""AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced that Howard Chang, M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024. Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner, M.D., executive vice president of Research and Development.""}, {""date"": ""20241121031006"", ""headline"": ""BPCIA Lawsuit Against Accord's Proposed Prolia\u00ae / Xgeva\u00ae Biosimilar Filed By Amgen"", ""summary"": ""On November 13, 2024, Amgen filed Case No. 5:24-cv-00642 against Accord BioPharma and Intas Pharmaceuticals, alleging INTP23, their proposed Prolia\u00ae / Xgeva\u00ae biosimilar, would infringe 34 of...""}, {""date"": ""20241121061414"", ""headline"": ""Wall Street awaits Amgen weight-loss drug data expected to move shares"", ""summary"": ""Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo...""}, {""date"": ""20241121070000"", ""headline"": ""Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop"", ""summary"": ""Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come.""}, {""date"": ""20241121094010"", ""headline"": ""Amgen picks prolific biotech founder Chang as new top scientist"", ""summary"": ""Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.""}, {""date"": ""20241121111414"", ""headline"": ""Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares"", ""summary"": ""Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo Nordisk.  Encouraging comments from Amgen about the 52-week Phase 2 trial helped fuel an 8% rise in the company's shares over the past year.  Amgen has said its drug could offer quicker weight loss and possibly better weight maintenance, as well as fewer shots, than once-weekly GLP-1s such as Novo's Wegovy and Lilly's Zepbound.""}, {""date"": ""20241121120114"", ""headline"": ""Amgen and Pfizer appoint new Science executives"", ""summary"": ""Several new appointments were announced by Amgen and Pfizer yesterday, focusing on R&D functions.Pfizer Inc. is appointing Dr Chris Boshoff, PhD, as Chief Scientific Officer and ...""}, {""date"": ""20241121163900"", ""headline"": ""Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains"", ""summary"": ""Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains""}, {""date"": ""20241122031007"", ""headline"": ""Amgen Files BPCIA Complaint Against Accord Biopharma Regarding Denosumab Biosimilar"", ""summary"": ""On November 13, 2024, Amgen filed a BPCIA complaint in the District Court for the Eastern District of North Carolina against Accord Biopharma, Inc.; Accord Healthcare, Inc.; and Intas Pharmaceuticals,...""}, {""date"": ""20241122124104"", ""headline"": ""Amgen : Reflecting on Two Patients\u2019 Perseverance and Strength During Lung Cancer Awareness Month"", ""summary"": ""Desiree and Vickie were each living seemingly normal lives until they were diagnosed with non-small cell lung cancer and small cell lung cancer , respectively. [...]This is an abstract of the...""}, {""date"": ""20241122130025"", ""headline"": ""RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?"", ""summary"": ""Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs.""}, {""date"": ""20241122144011"", ""headline"": ""Why Amgen (AMGN) is a Top Value Stock for the Long-Term"", ""summary"": ""Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.""}, {""date"": ""20241122151043"", ""headline"": ""AbbVie: Upgrading To 'Strong Buy' After Pullback"", ""summary"": ""AbbVie\u00e2\u0080\u0099s high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.""}, {""date"": ""20241122163900"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Amgen Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241124140010"", ""headline"": ""Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 49% Undervaluation?"", ""summary"": ""Key Insights Amgen's estimated fair value is US$583 based on 2 Stage Free Cash Flow to Equity Current share price of...""}]",{}
3,2024-11-24,292.1695556640625,2024-12-01,280.6029968261719,-0.03958851500321925,D4,"[{""date"": ""20241124140010"", ""headline"": ""Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 49% Undervaluation?"", ""summary"": ""Key Insights Amgen's estimated fair value is US$583 based on 2 Stage Free Cash Flow to Equity Current share price of...""}, {""date"": ""20241125163800"", ""headline"": ""Amgen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Monday when compared to competitors""}, {""date"": ""20241126071408"", ""headline"": ""Weight-loss stocks get a boost from new Biden proposal on drug coverage, but will it hold up?"", ""summary"": ""Weight-loss stocks get a boost from new Biden proposal on drug coverage, but will it hold up?""}, {""date"": ""20241126084005"", ""headline"": ""Amgen : MariTide Topline Phase 2 Results"", ""summary"": ""MariTide Update November 26, 2024 Today's Presenters Bob...""}, {""date"": ""20241126085430"", ""headline"": ""Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test"", ""summary"": ""Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test""}, {""date"": ""20241126091500"", ""headline"": ""Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know."", ""summary"": ""Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.""}, {""date"": ""20241126094500"", ""headline"": ""Amgen, Boeing share losses lead Dow's 200-point fall"", ""summary"": ""Amgen, Boeing share losses lead Dow's 200-point fall""}, {""date"": ""20241126094600"", ""headline"": ""Amgen\u2019s stock may see worst day in 24 years as weight-loss-drug data underwhelms"", ""summary"": ""Amgen\u2019s stock may see worst day in 24 years as weight-loss-drug data underwhelms""}, {""date"": ""20241126095000"", ""headline"": ""These Stocks Are Moving the Most Today: GM, Ford, Amgen, Eli Lilly, Super Micro, Rivian, Analog Devices, Kohl\u2019s, and More"", ""summary"": ""These Stocks Are Moving the Most Today: GM, Ford, Amgen, Eli Lilly, Super Micro, Rivian, Analog Devices, Kohl\u2019s, and More""}, {""date"": ""20241126103725"", ""headline"": ""Dow Jones Falls On Trump Tariff Risk As Fed Minutes Loom; Nvidia Rises But Retailers Dive On Earnings (Live Coverage)"", ""summary"": ""Dow Jones Falls On Trump Tariff Risk As Fed Minutes Loom; Nvidia Rises But Retailers Dive On Earnings (Live Coverage)""}, {""date"": ""20241126104948"", ""headline"": ""Amgen drags Dow lower after weight-loss drug data disappoints Wall Street"", ""summary"": ""Amgen drags Dow lower after weight-loss drug data disappoints Wall Street""}, {""date"": ""20241126120000"", ""headline"": ""AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM"", ""summary"": ""Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to discuss data from the 52-week, Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and progress on its development program. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.""}, {""date"": ""20241126123400"", ""headline"": ""Amgen Obesity Drug Cut Weight In Closely Watched Study"", ""summary"": ""A highly anticipated obesity-drug candidate from biotech  Amgen  helped patients shed a significant amount of weight in a midstage study.  Subjects taking Amgen\u2019s MariTide lost 20% of their body weight compared with those who received placebos, Amgen said Tuesday.  Analysts had generally expected the drug to achieve weight reduction of 20% or more.""}, {""date"": ""20241126131131"", ""headline"": ""Amgen falls after obesity study results"", ""summary"": ""Investing.com -- Shares of Amgen (NASDAQ: NASDAQ:AMGN) dropped 12% Tuesday following the release of Phase 2 trial results for its obesity drug candidate, MariTide (formerly AMG 133).""}, {""date"": ""20241126133656"", ""headline"": ""Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau"", ""summary"": ""On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) in obese patients. The company said that MariTide demonstrated up to ~20% average weight loss at one year (52 weeks) without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks. Amgen\u2019s stock dropped as the results seemed to fall short of Wall Street\u2019s high ex""}, {""date"": ""20241126134816"", ""headline"": ""Update: Amgen Says Phase 2 Study Shows MariTide Achieves up to 20% Weight Loss in One Year"", ""summary"": ""(Updates with additional details throughout the story and the latest stock movement in the seventh paragraph.""}, {""date"": ""20241126134900"", ""headline"": ""Medicare Could Pay for Wegovy. Don\u2019t Count On It."", ""summary"": ""Medicare Could Pay for Wegovy. Don\u2019t Count On It.""}, {""date"": ""20241126141427"", ""headline"": ""Sector Update: Health Care Stocks Mixed Premarket Tuesday"", ""summary"": ""Health care stocks were mixed premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) was 0.""}, {""date"": ""20241126141657"", ""headline"": ""Amgen shows 20% weight loss in once-monthly injectable MariTide"", ""summary"": ""Amgen's latest once-monthly weight loss drug data looks \""OK,\"" analysts say, as its path to approval still remains murky.""}, {""date"": ""20241126143341"", ""headline"": ""Stocks Open Mixed. Amgen Is Dragging on the Dow."", ""summary"": ""Stocks were mixed to start the day on Tuesday as markets reacted to a wave of earnings reports and economic data.  There\u2019s also President-elect Donald Trump\u2019s plans for tariffs on Mexico, Canada, and China for Wall Street to digest.  The Dow Jones Industrial Average was down 157 points, or 0.4%.""}, {""date"": ""20241126143840"", ""headline"": ""Amgen Falls as Weight-Loss Shot  Results Disappoint Street"", ""summary"": ""(Bloomberg) -- Amgen Inc. shares fell the most in 23 years after its experimental obesity shot failed to outperform those of rivals and showed a high rate of side effects.Most Read from BloombergNew York City\u2019s \u2018Living Breakwaters\u2019 Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women\u2019s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets Historic Push for 80,000 Homes With $5 Billion PledgeThe reaction shows how high the bar is for""}, {""date"": ""20241126150308"", ""headline"": ""Amgen: MariTide Underwhelms, But There Are Ways To Win"", ""summary"": ""Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.""}, {""date"": ""20241126150400"", ""headline"": ""Amgen Stock Dives After Weight-Loss Drug Data. Here\u2019s What to Know."", ""summary"": ""The pharmaceutical company's MariTide treatment performs well in a phase 2 study but not as well as Wall Street expected.""}, {""date"": ""20241126165632"", ""headline"": ""Amgen stock slips as obesity drug study disappoints Wall Street"", ""summary"": ""Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly obesity drug MariTide. Despite the medication demonstrating the ability to reduce an individual's body weight by 20%, the stock tumbled as the results fell short of investor expectations. Yahoo Finance Health Reporter Anjalee Khemlani delves into the details of the study, exploring the potential strategic routes Amgen could pursue to position the drug competitively in the growing GLP-1 weight loss market. To watch more expert insights and analysis on the latest market action, check out more Catalysts\u00a0here. This post was written by Angel Smith""}, {""date"": ""20241126165733"", ""headline"": ""Top Midday Stories: Automaker Shares Fall on New Trump Tariff Threat; Amgen Shares Tumble on Obesity Drug Study Results"", ""summary"": ""The Nasdaq Composite and S&P 500 Index were both up in late-morning trading Tuesday, while the Dow Jones Industrial Average was down, as Wall Street assesses the potential impact of tariffs promised by President-elect Donald Trump.""}, {""date"": ""20241126170343"", ""headline"": ""Top Stock Movers Now: Amgen, Best Buy, JM Smucker, and More"", ""summary"": ""U.S. equities were mixed at midday following comments from President-elect Trump about new tariffs on Chinese, Canadian, and Mexican imports.""}, {""date"": ""20241126180149"", ""headline"": ""Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed"", ""summary"": ""Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn\u2019t very impressed.""}, {""date"": ""20241126182844"", ""headline"": ""Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations"", ""summary"": ""A Phase 2 study of Amgen's experimental weight-loss treatment didn't meet expectations of analysts.""}, {""date"": ""20241126190354"", ""headline"": ""Amgen share price plummets despite Phase II weight loss success"", ""summary"": ""Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had hoped for more.""}, {""date"": ""20241126210006"", ""headline"": ""Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline"", ""summary"": ""Shares of Amgen (AMGN) fell on Tuesday after the biotech company reported results for a phase 2 study of its obesity injection, which fell short of efficacy expectations, Mizuho Securities said.""}, {""date"": ""20241126212025"", ""headline"": ""Dow Jones, S&P 500 At New High After Fed Minutes; Dell, Workday, CrowdStrike Report (Live Coverage)"", ""summary"": ""The Dow Jones Industrial Average fell after news that President-elect Trump may impose tariffs on goods from China, Mexico and Canada.""}, {""date"": ""20241126221630"", ""headline"": ""Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment"", ""summary"": ""Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.""}, {""date"": ""20241127030105"", ""headline"": ""Wall Street Breakfast Podcast: Trump's Tariff Threats, Fed Signals"", ""summary"": ""Investors set aside Trump's new tariff threats and Fed signals moderate pace in cutting rates.""}, {""date"": ""20241127031308"", ""headline"": ""Unexpected Results In Hatch Waxman Litigation: A Review Of Legal Decisions From 2023"", ""summary"": ""Patent owners generally look to secondary indicia to bolster their nonobvious defenses when prior art and/or knowledge of a person of ordinary skill in the art seem to make the obviousness decision a...""}, {""date"": ""20241127043945"", ""headline"": ""Amgen: Checks All The Wrong Boxes"", ""summary"": ""Amgen's dividend yield is not attractive enough, and the stock's technical damage indicates further potential declines. See why AMGN is a Sell.""}, {""date"": ""20241127071000"", ""headline"": ""What Holidays? Inflation, Black Friday, Bitcoin, and More Market Concerns This Thanksgiving. And 5 Other Things to Know Today."", ""summary"": ""What Holidays? Inflation, Black Friday, Bitcoin, and More Market Concerns This Thanksgiving. And 5 Other Things to Know Today.""}, {""date"": ""20241127085700"", ""headline"": ""Why Amgen's Weight Loss Result Is a Win for Eli Lilly"", ""summary"": ""Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate.  According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.  On the surface, 20% weight loss after 52 weeks for a monthly injection is commendable.""}, {""date"": ""20241127101615"", ""headline"": ""AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY"", ""summary"": ""THOUSAND OAKS - Amgen today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide , an investigational antibody peptide conjugate subcutaneously administered...""}, {""date"": ""20241127121055"", ""headline"": ""Amgen\u2019s MariTide shows up to 20% average weight loss in Phase 2 study"", ""summary"": ""Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide \u2013 maridebart cafraglutide, formerly AMG 133 -, an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people living with obesity or overweight without Type 2 diabetes, MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks. People livin""}, {""date"": ""20241127124449"", ""headline"": ""Amgen's Obesity Candidate MariTide Must Mitigate Tolerability Issues to Compete with Blockbuster Tirzepatide, Truist Says"", ""summary"": ""Amgen's (AMGN) investigational drug MariTide is a good opportunity for the company to enter the obes""}, {""date"": ""20241127130658"", ""headline"": ""Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You"", ""summary"": ""Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.""}, {""date"": ""20241127200000"", ""headline"": ""AMGN Stock Down Despite Strong Data From Obesity Drug Study"", ""summary"": ""Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.""}, {""date"": ""20241128060645"", ""headline"": ""Alumis: A Best-In-Class TYK2 Inhibitor"", ""summary"": ""Alumis is advancing ESK-001 for plaque psoriasis with phase 3 data expected in 2026. Read why ALMS stock is compelling yet requires caution on safety data.""}, {""date"": ""20241128085500"", ""headline"": ""Janus Henderson Global Life Sciences Fund Q3 2024 Commentary"", ""summary"": ""Janus Henderson Global Life Sciences Fund returned 5.39% and the MSCI World Health Care IndexSM returned 5.70%. Read more here.""}, {""date"": ""20241128120028"", ""headline"": ""Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 56% Return On Equity?"", ""summary"": ""Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...""}, {""date"": ""20241129005000"", ""headline"": ""Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary"", ""summary"": ""The Janus Henderson Global Life Sciences Diversified ADR Managed Account\u00c2\u00a0Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.""}, {""date"": ""20241129092800"", ""headline"": ""Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?"", ""summary"": ""Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market rose nearly 3% in the same period.  The clear culprit for the drop is, quite regrettably for shareholders, an unintentional disclosure of clinical trial information that the market found to be rather unappetizing.  During clinical trials, especially those in phase 1 safety testing, investigators are obligated to capture a wide variety of biometric data, including for many factors that are of unknown or ancillary importance.""}, {""date"": ""20241129112800"", ""headline"": ""Boeing, NVIDIA Corp. share gains contribute to Dow's 261-point jump"", ""summary"": ""Boeing, NVIDIA Corp. share gains contribute to Dow's 261-point jump""}, {""date"": ""20241129140011"", ""headline"": ""Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.""}, {""date"": ""20241129163900"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Amgen Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241129190657"", ""headline"": ""Wide Trading Range For Amgen Stock Makes This Option Shine"", ""summary"": ""Amgen posted earnings that were better than expected last month.  Because Amgen stock has heavy institutional ownership, this allows us a unique opportunity to capture time value as the stock regains its footing.  Once again, we'll use a short iron condor that trades the wider ranges in Amgen.""}, {""date"": ""20241129213000"", ""headline"": ""AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE"", ""summary"": ""Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney, executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the interne""}, {""date"": ""20241130003445"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 1"", ""summary"": ""Stay updated on dividend activity with our weekly summary for Dividend Champions, Contenders, and Challengers, including upcoming ex-dividend and pay dates.""}, {""date"": ""20241130112000"", ""headline"": ""Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?"", ""summary"": ""The market didn't appreciate Amgen's (NASDAQ: AMGN) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 from the previous day's close, though they recovered to close just 4.7% down for the day.  Amgen is looking to compete in the all-important market for anti-obesity medicines, facing off against the reigning champions, Eli Lilly and Novo Nordisk (NYSE: NVO).  Over the course of 52 weeks of treatment, Zepbound helps patients lose on average 24% of their mass, whereas Wegovy has been shown in clinical trials to lead to a 14% reduction in mass.""}, {""date"": ""20241130120000"", ""headline"": ""Eli Lilly and Novo Nordisk\u2019s Obesity Moat Just Got Stronger"", ""summary"": ""Data from their most serious competitor, Amgen, suggests the biotech won\u2019t upstage the market leaders.""}, {""date"": ""20241201001816"", ""headline"": ""Amgen Inc. (AMGN): A Bull Case Theory"", ""summary"": ""We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics\u2019 Substack by Magnus Ofstad. In this article, we will summarize the bulls\u2019 thesis on AMGN. Amgen Inc. (AMGN)\u2019s share was trading at $280.07 as of Nov 27th. AMGN\u2019s trailing and forward P/E were 35.77 and 13.57 respectively according to Yahoo Finance. Amgen (AMGN) presents [\u2026]""}, {""date"": ""20241201203419"", ""headline"": ""December Is Best For Stocks But Prepare For January 6"", ""summary"": ""December is the best month for stocks, but expect potential profit-taking in the first week of January. Read why investors should focus on stock picking.""}, {""date"": ""20241201211235"", ""headline"": ""Mastercard, Broadcom, Pfizer Among Two Dozen Companies To Announce Dividend Increases In December"", ""summary"": ""It\u00e2\u0080\u0099ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the companies with dividend increases.""}]",{}
4,2024-12-01,280.6029968261719,2024-12-08,270.39544677734375,-0.03637719541231954,D4,"[{""date"": ""20241201001816"", ""headline"": ""Amgen Inc. (AMGN): A Bull Case Theory"", ""summary"": ""We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics\u2019 Substack by Magnus Ofstad. In this article, we will summarize the bulls\u2019 thesis on AMGN. Amgen Inc. (AMGN)\u2019s share was trading at $280.07 as of Nov 27th. AMGN\u2019s trailing and forward P/E were 35.77 and 13.57 respectively according to Yahoo Finance. Amgen (AMGN) presents [\u2026]""}, {""date"": ""20241201203419"", ""headline"": ""December Is Best For Stocks But Prepare For January 6"", ""summary"": ""December is the best month for stocks, but expect potential profit-taking in the first week of January. Read why investors should focus on stock picking.""}, {""date"": ""20241201211235"", ""headline"": ""Mastercard, Broadcom, Pfizer Among Two Dozen Companies To Announce Dividend Increases In December"", ""summary"": ""It\u00e2\u0080\u0099ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the companies with dividend increases.""}, {""date"": ""20241202094619"", ""headline"": ""AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE"", ""summary"": ""THOUSAND OAKS - Amgen will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024.Peter Griffith, executive vice president and chief financial officer...""}, {""date"": ""20241202095100"", ""headline"": ""Amgen, Nike share losses lead Dow's 115-point drop"", ""summary"": ""Amgen, Nike share losses lead Dow's 115-point drop""}, {""date"": ""20241202130000"", ""headline"": ""This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?"", ""summary"": ""The biotech industry can be volatile even for relatively large companies.  Amgen (NASDAQ: AMGN), one of the more prominent names in the game, just reminded us all of that fact.  Let's find out what the future holds for Amgen after its massive one-day drop.""}, {""date"": ""20241202163900"", ""headline"": ""Amgen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Monday when compared to competitors""}, {""date"": ""20241202210000"", ""headline"": ""AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE"", ""summary"": ""Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday, Dec. 5, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney, executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simul""}, {""date"": ""20241203073000"", ""headline"": ""Bargain Hunting In A Pricey Market: 2 High-Yield Dividend Picks That Have Me Hooked"", ""summary"": ""High-yield bargain opportunities exist for disciplined, value-focused investors. Read more about the two standout stocks I've identified.""}, {""date"": ""20241203163900"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Amgen Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241204132900"", ""headline"": ""Amgen Stock Falls 12% in a Month: Should You Buy the Dip?"", ""summary"": ""AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested in the stock for now.""}, {""date"": ""20241204135300"", ""headline"": ""Biggest Winners And Losers Since The Election"", ""summary"": ""Of the 13 biggest stock winners, most of them were already big winners leading up to the election, and all but four are currently up over 40% YTD. Click to read.""}, {""date"": ""20241204142722"", ""headline"": ""Amgen Inc. (AMGN) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)"", ""summary"": ""Amgen Inc. (NASDAQ:AMGN) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 10:00 AM ETCompany ParticipantsPeter Griffith - Executive...""}, {""date"": ""20241204163900"", ""headline"": ""Amgen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Amgen Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20241204173718"", ""headline"": ""Dow 30 December Dogs Show 28 Pay Dividends And 1 \""Safer\"" Buy"", ""summary"": ""While most of this collection of Dow Industrials is too pricey and reveals only skinny dividends, one of the ten lowest priced Dogs of the Dow is ready to buy. Read on to find out which one.""}, {""date"": ""20241204212800"", ""headline"": ""Top Stock Reports for Amgen, Eaton & Enzo Biochem"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Eaton Corp. plc (ETN) and Sony Group Corp. (SONY), as well as two micro-cap stocks, Moving iMage Technologies, Inc. (MITQ) and Enzo Biochem, Inc. (ENZ).""}, {""date"": ""20241205011511"", ""headline"": ""Update On Pending Denosumab BPCIA Litigations"", ""summary"": ""There are four pending BPCIA litigations brought by Amgen against biosimilar companies seeking to market denosumab biosimilars. Two of the four cases are pending in the District Court for the District...""}, {""date"": ""20241205094708"", ""headline"": ""Amgen Plans $1 Billion North Carolina Manufacturing Plant"", ""summary"": ""By Colin Kellaher Amgen on Thursday unveiled plans to spend $1 billion on a second drug-substance manufacturing plant in Holly Springs, N.C., boosting its total planned investment in the town to...""}, {""date"": ""20241205100000"", ""headline"": ""The Zacks Analyst Blog Highlights Amgen, Eaton, Sony, iMage and Enzo Biochem"", ""summary"": ""Amgen, Eaton, Sony, iMage and Enzo Biochem are included in this Analyst Blog.""}, {""date"": ""20241205113200"", ""headline"": ""LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study"", ""summary"": ""LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.""}, {""date"": ""20241205122800"", ""headline"": ""Is Amgen Still a Top Dividend Stock?"", ""summary"": ""The relationship between interest rates and dividend stocks tends to follow a predictable pattern.  Amgen (NASDAQ: AMGN) offers an intriguing test case for this dynamic heading into 2025.  In November, Amgen reported disappointing obesity-drug results.""}, {""date"": ""20241205140000"", ""headline"": ""AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA"", ""summary"": ""Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.""}, {""date"": ""20241205150009"", ""headline"": ""Boeing shares fall 1% as judge rejects plea deal"", ""summary"": ""Boeing shares fall 1% as judge rejects plea deal""}, {""date"": ""20241205155600"", ""headline"": ""UnitedHealth, Salesforce share losses contribute to Dow's 250-point drop"", ""summary"": ""UnitedHealth, Salesforce share losses contribute to Dow's 250-point drop""}, {""date"": ""20241205163900"", ""headline"": ""Amgen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Thursday when compared to competitors""}, {""date"": ""20241206081455"", ""headline"": ""Why Amgen Inc. (AMGN) Is Among the Best Affordable Stocks to Buy Right Now"", ""summary"": ""We recently published a list of 12 Best Affordable Stocks To Buy Right Now. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best affordable stocks to buy. Economic and Market Outlook 2025 There has been a growing debate regarding whether the economy of the United [\u2026]""}, {""date"": ""20241206110700"", ""headline"": ""AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B"", ""summary"": ""The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere,\u00a0Agenus cut spending and the U.S. PTO withdrew a controversial\u00a0proposed patent rule.""}, {""date"": ""20241206135052"", ""headline"": ""Johnson & Johnson Is A Better Dividend Stock Than Amgen In Our View"", ""summary"": ""Market concerns push Johnson & Johnson and Amgen Inc. stocks. JNJ a strong buy with timeless dividends advice, while AMGN is downgraded. Click for more.""}, {""date"": ""20241206154106"", ""headline"": ""A Fight for Hope: Inspiring Others Through Childhood B-ALL"", ""summary"": ""In the middle of an icy Texas night, Chaundra Dixon raced through treacherous roads with her young son, MJ, in the backseat. His pain grew steadily, with his condition worsening progressively until it...""}, {""date"": ""20241206163900"", ""headline"": ""Amgen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20241206182805"", ""headline"": ""Regeneron: Recent Bear Run May Be Justified - Pharma Faces A Testing 2025"", ""summary"": ""Regeneron Pharmaceuticals, Inc.'s stock faces challenges with Eylea's decline but potential growth from Dupixent. Find out why I maintain a Hold rating on REGN.""}, {""date"": ""20241207150000"", ""headline"": ""BLINCYTO\u00ae (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO\u00ae (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of""}, {""date"": ""20241207153900"", ""headline"": ""Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?"", ""summary"": ""Looking for reliable income in the stock market? You might want to consider the top Dogs of the Dow in December. Here's what you need to know about this trio of blue-chip stocks.""}]",{}
5,2024-12-08,270.39544677734375,2024-12-15,268.451171875,-0.0071904868425716195,D1,"[{""date"": ""20241209065100"", ""headline"": ""The Zacks Analyst Blog Eli Lilly, Novo Nordisk's  Amgen and Viking Therapeutics"", ""summary"": ""Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics are included in this Analyst Blog.""}, {""date"": ""20241209093600"", ""headline"": ""2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer"", ""summary"": ""Whether you're looking for a way to beat the benchmark S&P 500 index or you just want a steady flow of passive income, dividend-paying stocks are a great way to achieve your investment goals.  During the 50-year period that ended in 2023, dividend-paying stocks in the S&P 500 index delivered a 9.17% average annual return.  At recent prices, shares of Coca-Cola (NYSE: KO), and Amgen (NASDAQ: AMGN) offer dividend yields above 3%, plus there's a good chance they'll be able to raise their payouts for many years to come.""}, {""date"": ""20241209163900"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Amgen Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241209181500"", ""headline"": ""Goldman Sachs adds Burlington, removes Amgen from Conviction List"", ""summary"": ""Burlington Stores (BURL) and Air Lease (AL) are the latest additions to Goldman Sachs' US Conviction List, while Amgen (AMGN) and Global-E Online (GLBE) are out. Goldman Sachs Director of Americas Equity Research Steve Kron comes on to talk more about these picks and the selection process for the firm's conviction list. \""Consumers are in a really good spot to spend. So you think about the off-price retailers \u2014 they're they're in that sweet spot of consumers that are seeking value right now,\"" Kron tells Catalysts hosts Seana Smith and Madison Mills. \""Also higher income consumers that are looking to trade down for good brands and Burlington's been executing really well.\"" On tech giant Nvidia (NVDA), Kron is seeing the AI revolution entering its \""infrastructure build-out stage\"" while more companies like Salesforce (CRM) are beginning to deploy their artificial intelligence products. To watch more expert insights and analysis on the latest market action, check out more Catalysts\u00a0here. This post was written by Luke Carberry Mogan.""}, {""date"": ""20241210114200"", ""headline"": ""Moderna Stock Is Struggling. BofA Doesn\u2019t See Things Getting Better."", ""summary"": ""Moderna Stock Is Struggling. BofA Doesn\u2019t See Things Getting Better.""}, {""date"": ""20241210140011"", ""headline"": ""Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock"", ""summary"": ""Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.""}, {""date"": ""20241210144011"", ""headline"": ""Here's Why Amgen (AMGN) is a Strong Value Stock"", ""summary"": ""The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.""}, {""date"": ""20241210144030"", ""headline"": ""BofA reinstates pharma coverage"", ""summary"": ""Investing.com -- Bank of America reinstated coverage of 11 major U.S. pharmaceutical and biotech stocks in a note Tuesday, highlighting mixed sector fundamentals.""}, {""date"": ""20241210163900"", ""headline"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20241210171626"", ""headline"": ""Amgen Boosts Quarterly Dividend by Nearly 6%"", ""summary"": ""By Kailyn Rhone The board of Amgen boosted its quarter dividend by almost 6%. The Thousand Oaks, Calif.-based biotechnology company said Tuesday that it raised its dividend to $2.38 per share...""}, {""date"": ""20241210213000"", ""headline"": ""AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025, to all stockholders of record as of the close of business on February 14, 2025.""}, {""date"": ""20241211163900"", ""headline"": ""Amgen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Amgen Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20241211170907"", ""headline"": ""Amgen's Nobel Laureate Network: A Catalyst for Innovation"", ""summary"": ""The exceptional caliber of scientists at Amgen is evident not only in the groundbreaking research they conduct, but also in where they train. A number of the company's researchers come from the labs...""}, {""date"": ""20241211225017"", ""headline"": ""Amgen (AMGN) Stock Sinks As Market Gains: Here's Why"", ""summary"": ""Amgen (AMGN) reachead $273.41 at the closing of the latest trading day, reflecting a -0.85% change compared to its last close.""}, {""date"": ""20241212123831"", ""headline"": ""Why Amgen Inc. (AMGN) Is the Best Safe Stock to Buy According to Analysts?"", ""summary"": ""We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best safe stocks to buy according to analysts. Market Will End 2024 Positively, Strategist Says Statistically, November and December tend to be [\u2026]""}, {""date"": ""20241212144511"", ""headline"": ""Why Amgen (AMGN) is a Top Growth Stock for the Long-Term"", ""summary"": ""Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.""}, {""date"": ""20241213095924"", ""headline"": ""Amgen to build $1B North Carolina pharmaceutical plant"", ""summary"": ""The drug substance factory in Holly Springs will create 370 new jobs and is its second\u00a0location\u00a0in the Research Triangle area.""}, {""date"": ""20241213100300"", ""headline"": ""Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling."", ""summary"": ""Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.""}, {""date"": ""20241213122300"", ""headline"": ""Dow's 112-point fall led by losses in NVIDIA Corp., Amgen shares"", ""summary"": ""Dow's 112-point fall led by losses in NVIDIA Corp., Amgen shares""}, {""date"": ""20241213163900"", ""headline"": ""Amgen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20241213214012"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 15"", ""summary"": ""Stay updated on dividend activity for top companies, including changes in dividends and upcoming ex-dividend and pay dates.""}, {""date"": ""20241213235416"", ""headline"": ""Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value"", ""summary"": ""Learn how to maximize returns by focusing on high-conviction stocks across diverse sectors and using proven investment strategies.""}, {""date"": ""20241214073157"", ""headline"": ""DJD: The Dogs Of The Dow ETF Not Ideal Heading Into 2025"", ""summary"": ""Discover why the Invesco Dow Jones Industrial Average Dividend ETF (DJD) may not be the best choice for investors seeking growth and performance.""}, {""date"": ""20241214150041"", ""headline"": ""How Much Would It Take To Earn $100 A Month From Amgen Stock"", ""summary"": ""Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures and delivers human therapeutics worldwide. It will report its Q4 2024 earnings on Feb. 4, 2025. Wall Street analysts expect the company to post an EPS of $5.03, up from $4.71 in the year-ago ...""}]",{}
6,2024-12-15,268.451171875,2024-12-22,261.2691955566406,-0.026753380393897297,D3,"[{""date"": ""20241216130059"", ""headline"": ""Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?"", ""summary"": ""The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others are coming.""}, {""date"": ""20241216130315"", ""headline"": ""Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation"", ""summary"": ""Upstream Bio is leveraging TSLP targeting for respiratory disorders treatment, with IPO funds and upcoming Chronic Rhinosinusitis data. Click for more on UPB.""}, {""date"": ""20241216142842"", ""headline"": ""Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease"", ""summary"": ""Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell.""}, {""date"": ""20241216162342"", ""headline"": ""Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen"", ""summary"": ""Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell.""}, {""date"": ""20241216163900"", ""headline"": ""Amgen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Amgen Inc. stock outperforms competitors despite losses on the day""}, {""date"": ""20241217115603"", ""headline"": ""Is Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?"", ""summary"": ""We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at some [\u2026]""}, {""date"": ""20241217124133"", ""headline"": ""Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)"", ""summary"": ""Viridian Therapeutics, Inc.'s stock soars on positive trial results, analysts bullish on FDA approval in 2026. Read more on VRDN stock prospects.""}, {""date"": ""20241217163900"", ""headline"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20241217225014"", ""headline"": ""Amgen (AMGN) Stock Moves -0.21%: What You Should Know"", ""summary"": ""In the most recent trading session, Amgen (AMGN) closed at $265.95, indicating a -0.21% shift from the previous trading day.""}, {""date"": ""20241217230823"", ""headline"": ""Why the Dow is suddenly in a historic funk"", ""summary"": ""The Dow Jones Industrial Average has fallen for nine straight trading sessions, marking its worst losing streak since 1978.""}, {""date"": ""20241218105602"", ""headline"": ""Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation"", ""summary"": ""Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the biopharmaceutical company. Read more here.""}, {""date"": ""20241218163900"", ""headline"": ""Amgen Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Wednesday when compared to competitors""}, {""date"": ""20241219112038"", ""headline"": ""Why Is Amgen Inc. (AMGN) Among the Best Dividend Stocks to Invest In?"", ""summary"": ""We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other dividend stocks. Dividend-focused investors are often drawn to stocks with high yields, shaping their strategies around acquiring such investments. A [\u2026]""}, {""date"": ""20241219163900"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Amgen Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20241220103000"", ""headline"": ""Goldman Sachs, Salesforce share gains lead Dow's 300-point jump"", ""summary"": ""Goldman Sachs, Salesforce share gains lead Dow's 300-point jump""}, {""date"": ""20241220120309"", ""headline"": ""Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump."", ""summary"": ""Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped""}, {""date"": ""20241220133300"", ""headline"": ""Dow up 650 points on gains for shares of Goldman Sachs, NVIDIA Corp."", ""summary"": ""Dow up 650 points on gains for shares of Goldman Sachs, NVIDIA Corp.""}, {""date"": ""20241220163900"", ""headline"": ""Amgen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Amgen Inc. stock rises Friday, still underperforms market""}, {""date"": ""20241220183609"", ""headline"": ""Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge."", ""summary"": ""Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.""}, {""date"": ""20241220194800"", ""headline"": ""Novo Nordisk Shares Plunge After New Obesity Shot Disappoints"", ""summary"": ""Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company\u2019s next blockbuster weight loss drug.""}, {""date"": ""20241221123043"", ""headline"": ""Novo obesity data positive for Eli Lilly and Amgen, says UBS"", ""summary"": ""UBS analyst Trung Huynh says Novo Nordisk\u2019s (NVO) CagriSema Phase 3 topline obesity data \u201cunderwhelmed,\u201d a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo\u2019s prior guidance of 25% and inferior to Lilly\u2019s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema\u2019s obesity readout a positive read-through to Lilly, \u201cvalidating again tirzepatide\u2019s best-in-class profile.\u201d It also""}, {""date"": ""20241222083651"", ""headline"": ""BME: 8.4% Yield From An Undervalued Sector"", ""summary"": ""An analysis of BlackRock Health Sciences Trust, previously rated as a hold, now considered a Buy due to sector overselling and potential growth.""}]",{}
7,2024-12-22,261.2691955566406,2024-12-29,260.5450439453125,-0.0027716685458663015,D1,"[{""date"": ""20241222083651"", ""headline"": ""BME: 8.4% Yield From An Undervalued Sector"", ""summary"": ""An analysis of BlackRock Health Sciences Trust, previously rated as a hold, now considered a Buy due to sector overselling and potential growth.""}, {""date"": ""20241223093200"", ""headline"": ""2 Excellent Dividend Stocks to Buy on the Dip"", ""summary"": ""AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common.  Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.  The company's $8.7 billion buyout of Cerevel Therapeutics now looks like a waste of money after the leading asset it got from that transaction, emraclidine, failed a pair of phase 2 studies.""}, {""date"": ""20241223122204"", ""headline"": ""Hot Obesity Drug Market Will Keep Investors Gripped Next Year"", ""summary"": ""(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S\u2019s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma\u2019s hottest market.Most Read from BloombergReviving a Little-Known Modernist Landmark in BuffaloThe Architects Who Built MiamiHo Chi Minh City Opens First Metro Line After Years of DelayNew York\u2019s Congestion Pricing Plan Still Faces Legal HurdlesNew York City\u2019s Historic Preservation Movement Is Having a Midlife CrisisNovo sh""}, {""date"": ""20241223131600"", ""headline"": ""Lilly's Zepbound Receives FDA Approval for Sleep Apnea"", ""summary"": ""FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.""}, {""date"": ""20241223134800"", ""headline"": ""Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?"", ""summary"": ""Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.""}, {""date"": ""20241223140011"", ""headline"": ""Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""20241223154600"", ""headline"": ""Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength."", ""summary"": ""Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.""}, {""date"": ""20241223163900"", ""headline"": ""Amgen Inc. stock rises Monday, still underperforms market"", ""summary"": ""Amgen Inc. stock rises Monday, still underperforms market""}, {""date"": ""20241223225018"", ""headline"": ""Here's Why Amgen (AMGN) Gained But Lagged the Market Today"", ""summary"": ""The latest trading day saw Amgen (AMGN) settling at $264, representing a +0.24% change from its previous close.""}, {""date"": ""20241224163900"", ""headline"": ""Amgen Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Amgen Inc. stock rises Tuesday, still underperforms market""}, {""date"": ""20241224172000"", ""headline"": ""3 biggest catalysts expected for healthcare in 2025"", ""summary"": ""After an eventful year in the pharmaceutical and biotech industries, what lies ahead for the health landscape in 2025? Yahoo Finance senior health reporter Anjalee Khemlani outlines the three biggest catalysts for change and innovation for healthcare in the new year, including GLP-1 weight-loss drugs and proposed regulations on pharmacy benefit managers (PBMs) from the second Trump administration. To watch more expert insights and analysis on the latest market action, check out more Catalysts\u00a0here. This post was written by Luke Carberry Mogan.""}, {""date"": ""20241224194500"", ""headline"": ""What's next for GLP-1 weight-loss drugs in 2025?"", ""summary"": ""GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly (LLY) exploring broader applications beyond weight management, including heart disease and sleep apnea treatments. Yahoo Finance Health Reporter Anjalee Khemlani dives into the details, analyzing the outlook for GLP-1 drugs as markets head into 2025. Also, catch Anjalee Khemlani highlight the three biggest catalysts for the healthcare industry expected in the new year. To watch more expert insights and analysis on the latest market action, check out more Market Domination\u00a0here. This post was written by Angel Smith""}, {""date"": ""20241226093000"", ""headline"": ""2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone"", ""summary"": ""Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.""}, {""date"": ""20241226093036"", ""headline"": ""PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr."", ""summary"": ""This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.""}, {""date"": ""20241227070000"", ""headline"": ""3 Healthcare Stocks to Buy for a 2025 Rebound"", ""summary"": ""Healthcare stocks have gotten crushed in 2024, and next year doesn\u2019t look much better.  Recent developments, including a bipartisan bill calling for insurers to separate from their pharmacy benefit management units, or PBMs, has caused pain, but the sector has been unloved for most of the last 11 months and change.""}, {""date"": ""20241227144010"", ""headline"": ""Are You a Value Investor? This 1 Stock Could Be the Perfect Pick"", ""summary"": ""Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.""}]",{}
8,2024-12-29,260.5450439453125,2025-01-05,259.12652587890625,-0.00544442544339474,D1,"[{""date"": ""20241230190239"", ""headline"": ""Chevron, Kimberly-Clark Among 15 Companies To Announce Dividend Increases In January"", ""summary"": ""Get the scoop on upcoming dividend increases from companies with long-term growth histories, including modest increases from Chevron and Kimberly-Clark in...""}, {""date"": ""20241230213613"", ""headline"": ""Is Amgen Inc. (AMGN) the Best Pharma Dividend Stock to Buy In 2024?"", ""summary"": ""We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower [\u2026]""}, {""date"": ""20241230230019"", ""headline"": ""Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights"", ""summary"": ""Amgen (AMGN) closed at $259.30 in the latest trading session, marking a -1.28% move from the prior day.""}, {""date"": ""20241231000100"", ""headline"": ""This Biotech Is One of the S&P 500\u2019s Worst Performers. It Looks Too Cheap."", ""summary"": ""This Biotech Is One of the S&P 500\u2019s Worst Performers. It Looks Too Cheap.""}, {""date"": ""20241231124952"", ""headline"": ""Akero Therapeutics: Where This Potential MASH Play Stands Currently"", ""summary"": ""Discover the latest on Akero Therapeutics, Inc., a biotech firm focusing on metabolic balance therapies, with a market cap of $2 billion. Click for my AKRO update.""}, {""date"": ""20241231214858"", ""headline"": ""GLP-1 questions emerge for 2025"", ""summary"": ""The 2025 outlook for GLP-1s isn't as bullish as it once was, but all hope is not lost.""}, {""date"": ""20241231225018"", ""headline"": ""Amgen (AMGN) Advances While Market Declines: Some Information for Investors"", ""summary"": ""Amgen (AMGN) closed at $260.64 in the latest trading session, marking a +0.52% move from the prior day.""}, {""date"": ""20250101120300"", ""headline"": ""The 5 worst-performing stocks on the Dow Jones Industrial Average in 2024"", ""summary"": ""The Dow's biggest losers include companies in the aerospace, biopharma, and sports apparel sectors.""}, {""date"": ""20250102052000"", ""headline"": ""Not A Year For The 2024 Dogs Of The Dow"", ""summary"": ""With the close of trading for 2024 occurring on Tuesday, it is time to look at the performance of those Dogs of the Dow. Read more here.""}, {""date"": ""20250102122143"", ""headline"": ""January Dow Dogs: 1 'Safer' Buy, And 5 With Promise"", ""summary"": ""Get insights on top Dow Dogs like Verizon and Merck, with potential net gains forecasted by analysts. Click for the January picks.""}, {""date"": ""20250102163900"", ""headline"": ""Amgen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Thursday when compared to competitors""}, {""date"": ""20250103133000"", ""headline"": ""Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?"", ""summary"": ""The Dow Jones Industrial Average\u00a0contains 30 handpicked companies that are, or at least once were, leaders in their respective industries.  Right now the three highest yielding Dow stocks are Verizon Communications\u00a0(NYSE: VZ), Chevron (NYSE: CVX), and Amgen (NASDAQ: AMGN).  Verizon is one of the largest telecom companies in the United States.""}, {""date"": ""20250103140012"", ""headline"": ""Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""20250103163900"", ""headline"": ""Amgen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Amgen Inc. stock rises Friday, still underperforms market""}, {""date"": ""20250104114800"", ""headline"": ""Prediction: These 3 Healthcare Stocks Will Soar in 2025"", ""summary"": ""Here's why they chose Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), and Summit Therapeutics (NASDAQ: SMMT).  David Jagielski (Amgen): Shares of Amgen started crashing in late November following the release of data from a phase 2 clinical trial for its weight loss candidate, MariTide.""}, {""date"": ""20250105142227"", ""headline"": ""Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold"", ""summary"": ""Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical indicators.""}, {""date"": ""20250105191836"", ""headline"": ""Amgen: Blockbusters, Emerging Therapies, And Investment Potential"", ""summary"": ""Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy for long-term investors.""}]","{""assetTurnoverTTM"": 0.3647, ""bookValue"": 5877, ""cashRatio"": 0.5183341270184857, ""currentRatio"": 1.2568, ""ebitPerShare"": 4.2717, ""eps"": 1.159, ""ev"": 188228.53, ""fcfMargin"": 0.4843, ""fcfPerShareTTM"": 19.3593, ""grossMargin"": 0.6575, ""inventoryTurnoverTTM"": 1.557, ""longtermDebtTotalAsset"": 0.6157, ""longtermDebtTotalCapital"": 0.8571, ""longtermDebtTotalEquity"": 9.6221, ""netDebtToTotalCapital"": 0.7294, ""netDebtToTotalEquity"": 8.1889, ""netMargin"": 0.069, ""operatingMargin"": 0.2543, ""payoutRatioTTM"": 0.8622, ""pb"": 23.8391, ""peTTM"": 34.2549, ""pfcfTTM"": 13.4792, ""pretaxMargin"": 0.0861, ""psTTM"": 4.1917, ""quickRatio"": 0.9538, ""receivablesTurnoverTTM"": 4.7579, ""roaTTM"": 0.0446, ""roeTTM"": 0.6718, ""roicTTM"": 0.0603, ""rotcTTM"": 0.1101, ""salesPerShare"": 16.7948, ""sgaToSale"": 0.3425, ""totalDebtToEquity"": 10.2261, ""totalDebtToTotalAsset"": 0.6544, ""totalDebtToTotalCapital"": 0.9109, ""totalRatio"": 1.0684, ""period"": ""2024-12-31""}"
9,2025-01-05,259.12652587890625,2025-01-12,260.12841796875,0.0038664204154534865,U1,"[{""date"": ""20250105142227"", ""headline"": ""Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold"", ""summary"": ""Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical indicators.""}, {""date"": ""20250105191836"", ""headline"": ""Amgen: Blockbusters, Emerging Therapies, And Investment Potential"", ""summary"": ""Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy for long-term investors.""}, {""date"": ""20250106062523"", ""headline"": ""Amgen: Growth Potential Met By High Debt Levels"", ""summary"": ""Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain. Explore more details here.""}, {""date"": ""20250106073000"", ""headline"": ""Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)"", ""summary"": ""Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold to buy.""}, {""date"": ""20250106124344"", ""headline"": ""Amgen\u2019s Imdylltra wins conditional MHRA licence for lung cancer"", ""summary"": ""Amgen\u2019s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.""}, {""date"": ""20250106125157"", ""headline"": ""Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year"", ""summary"": ""Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.38 on 7th of...""}, {""date"": ""20250106171016"", ""headline"": ""Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?"", ""summary"": ""Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""20250106211200"", ""headline"": ""Top Analyst Reports for Microsoft, Exxon Mobil & Amgen"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Exxon Mobil Corporation (XOM) and Amgen Inc. (AMGN), as well as two micro-cap stocks PrimeEnergy Resources Corporation (PNRG) and FONAR Corporation (FONR).""}, {""date"": ""20250106230019"", ""headline"": ""Amgen (AMGN) Stock Sinks As Market Gains: Here's Why"", ""summary"": ""Amgen (AMGN) concluded the recent trading session at $258.59, signifying a -1.01% move from its prior day's close.""}, {""date"": ""20250107105800"", ""headline"": ""The Zacks Analyst Blog Highlights Microsoft, Exxon Mobil, Amgen, PrimeEnergy Resources and FONAR"", ""summary"": ""Microsoft, Exxon Mobil, Amgen, PrimeEnergy Resources and FONAR are part of the Zacks top Analyst Blog.""}, {""date"": ""20250107113119"", ""headline"": ""Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)"", ""summary"": ""Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.""}, {""date"": ""20250107140013"", ""headline"": ""How to Find Strong Medical Stocks Slated for Positive Earnings Surprises"", ""summary"": ""Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.""}, {""date"": ""20250107164000"", ""headline"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains"", ""summary"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains""}, {""date"": ""20250107225021"", ""headline"": ""Amgen (AMGN) Advances While Market Declines: Some Information for Investors"", ""summary"": ""Amgen (AMGN) closed at $262.05 in the latest trading session, marking a +1.34% move from the prior day.""}, {""date"": ""20250108034200"", ""headline"": ""2024 Performance Review And Future Strategy"", ""summary"": ""My 2024 picks outperformed the S&P 500, mainly due to Tesla, but small biotech firms lagged significantly. Learn more about my 2024 performance here.""}, {""date"": ""20250108091655"", ""headline"": ""CURE: Analyst Estimates Point To Significant Gains In 2025"", ""summary"": ""The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks.""}, {""date"": ""20250108210100"", ""headline"": ""AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE"", ""summary"": ""Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.""}, {""date"": ""20250109111900"", ""headline"": ""Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug"", ""summary"": ""The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.""}, {""date"": ""20250109120000"", ""headline"": ""Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap"", ""summary"": ""Discover why SCHD is a clear buy with a look at its top 10 holdings and why they make it an attractive investment opportunity right now.""}, {""date"": ""20250109130003"", ""headline"": ""Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts."", ""summary"": ""Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.""}, {""date"": ""20250110163700"", ""headline"": ""Amgen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20250111044647"", ""headline"": ""Eli Lilly: Still Much Room To Ride The Weight-Loss Wave"", ""summary"": ""Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.""}]","{""assetTurnoverTTM"": 0.3647, ""bookValue"": 5877, ""cashRatio"": 0.5183341270184857, ""currentRatio"": 1.2568, ""ebitPerShare"": 4.2717, ""eps"": 1.159, ""ev"": 188228.53, ""fcfMargin"": 0.4843, ""fcfPerShareTTM"": 19.3593, ""grossMargin"": 0.6575, ""inventoryTurnoverTTM"": 1.557, ""longtermDebtTotalAsset"": 0.6157, ""longtermDebtTotalCapital"": 0.8571, ""longtermDebtTotalEquity"": 9.6221, ""netDebtToTotalCapital"": 0.7294, ""netDebtToTotalEquity"": 8.1889, ""netMargin"": 0.069, ""operatingMargin"": 0.2543, ""payoutRatioTTM"": 0.8622, ""pb"": 23.8391, ""peTTM"": 34.2549, ""pfcfTTM"": 13.4792, ""pretaxMargin"": 0.0861, ""psTTM"": 4.1917, ""quickRatio"": 0.9538, ""receivablesTurnoverTTM"": 4.7579, ""roaTTM"": 0.0446, ""roeTTM"": 0.6718, ""roicTTM"": 0.0603, ""rotcTTM"": 0.1101, ""salesPerShare"": 16.7948, ""sgaToSale"": 0.3425, ""totalDebtToEquity"": 10.2261, ""totalDebtToTotalAsset"": 0.6544, ""totalDebtToTotalCapital"": 0.9109, ""totalRatio"": 1.0684, ""period"": ""2024-12-31""}"
10,2025-01-12,260.12841796875,2025-01-19,269.9292297363281,0.03767682071843281,U4,"[{""date"": ""20250113055655"", ""headline"": ""SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate"", ""summary"": ""SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024. See why I rate SWTX stock a strong buy.""}, {""date"": ""20250113105703"", ""headline"": ""Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts."", ""summary"": ""Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.""}, {""date"": ""20250113125900"", ""headline"": ""UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb"", ""summary"": ""UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb""}, {""date"": ""20250113155300"", ""headline"": ""UnitedHealth, Caterpillar share gains lead Dow's 350-point climb"", ""summary"": ""UnitedHealth, Caterpillar share gains lead Dow's 350-point climb""}, {""date"": ""20250113181002"", ""headline"": ""Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025"", ""summary"": ""The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.""}, {""date"": ""20250113191425"", ""headline"": ""43rd Annual J.P. Morgan Healthcare Conference 2025"", ""summary"": ""The following slide deck was published by Amgen Inc.""}, {""date"": ""20250113203656"", ""headline"": ""Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)"", ""summary"": ""Amgen Inc. (NASDAQ:AMGN) 43rd Annual J.P.""}, {""date"": ""20250113213005"", ""headline"": ""Amgen : 43rd Annual JP Morgan Healthcare Conference Presentation"", ""summary"": ""43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ROBERT A. BRADWAY, CHAIRMAN AND CHIEF EXECUTIVE OFFICER January 13, 2025 ...""}, {""date"": ""20250114163700"", ""headline"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20250116060356"", ""headline"": ""Tempering Positive Sentiment Of AI In Biotech"", ""summary"": ""AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore more details here.""}, {""date"": ""20250117090205"", ""headline"": ""FDA APPROVES LUMAKRAS\u00ae (SOTORASIB) IN COMBINATION WITH VECTIBIX\u00ae (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER"", ""summary"": ""Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOCTHOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen today announced that the...""}, {""date"": ""20250117112704"", ""headline"": ""Amgen : Advancement in Combination Biomarker Driven Therapy for Adult Patients with Chemorefractory KRAS G12C Mutated Metastatic Colorectal Cancer (mCRC)"", ""summary"": ""Colorectal cancer is the third leading cause of cancer-related deaths in the United States.1 There is a critical need for more effective treatment options for patients with CRC, particularly for...""}, {""date"": ""20250119165445"", ""headline"": ""Top 4 Immunology Stocks Poised For Growth In 2025"", ""summary"": ""Discover the latest trends and developments in the global immunology drugs market, along with four promising stocks to watch for potential investments.""}]","{""assetTurnoverTTM"": 0.3647, ""bookValue"": 5877, ""cashRatio"": 0.5183341270184857, ""currentRatio"": 1.2568, ""ebitPerShare"": 4.2717, ""eps"": 1.159, ""ev"": 188228.53, ""fcfMargin"": 0.4843, ""fcfPerShareTTM"": 19.3593, ""grossMargin"": 0.6575, ""inventoryTurnoverTTM"": 1.557, ""longtermDebtTotalAsset"": 0.6157, ""longtermDebtTotalCapital"": 0.8571, ""longtermDebtTotalEquity"": 9.6221, ""netDebtToTotalCapital"": 0.7294, ""netDebtToTotalEquity"": 8.1889, ""netMargin"": 0.069, ""operatingMargin"": 0.2543, ""payoutRatioTTM"": 0.8622, ""pb"": 23.8391, ""peTTM"": 34.2549, ""pfcfTTM"": 13.4792, ""pretaxMargin"": 0.0861, ""psTTM"": 4.1917, ""quickRatio"": 0.9538, ""receivablesTurnoverTTM"": 4.7579, ""roaTTM"": 0.0446, ""roeTTM"": 0.6718, ""roicTTM"": 0.0603, ""rotcTTM"": 0.1101, ""salesPerShare"": 16.7948, ""sgaToSale"": 0.3425, ""totalDebtToEquity"": 10.2261, ""totalDebtToTotalAsset"": 0.6544, ""totalDebtToTotalCapital"": 0.9109, ""totalRatio"": 1.0684, ""period"": ""2024-12-31""}"
11,2025-01-19,269.9292297363281,2025-01-26,273.2127380371094,0.012164330272748325,U2,"[{""date"": ""20250119165445"", ""headline"": ""Top 4 Immunology Stocks Poised For Growth In 2025"", ""summary"": ""Discover the latest trends and developments in the global immunology drugs market, along with four promising stocks to watch for potential investments.""}, {""date"": ""20250120102609"", ""headline"": ""AMGEN - FDA APPROVES LUMAKRAS IN COMBINATION WITH VECTIBIX FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER"", ""summary"": ""THOUSAND OAKS - Amgen today announced that the U.S. Food and Drug Administration has approved LUMAKRAS in combination with Vectibix for the treatment of adult patients with KRAS G12C-mutated...""}, {""date"": ""20250120131350"", ""headline"": ""Amgen: Likely To Be Rangebound (Rating Downgrade)"", ""summary"": ""Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives for biotech investors right now.""}, {""date"": ""20250121070000"", ""headline"": ""Aristotle Value Equity Q4 2024 Commentary"", ""summary"": ""For Q4 2024, Aristotle Capital\u00e2\u0080\u0099s Value Equity Composite posted a total return of -4.09% gross of fees. Read more here.""}, {""date"": ""20250121164300"", ""headline"": ""Arcus Taps Amgen Exec Richard Markus as Chief Medical Officer"", ""summary"": ""Arcus Taps Amgen Exec Richard Markus as Chief Medical Officer""}, {""date"": ""20250123041749"", ""headline"": ""How To Invest $100,000 In The Ten Cheapest Dow Dividend 100 Stocks"", ""summary"": ""SCHD is one of my favorite dividend funds. Check out the Top 20 holdings of SCHD and score them according to which, I believe, are the top 10 cheapest of the lot.""}, {""date"": ""20250123163500"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Amgen Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20250124091500"", ""headline"": ""DIVO: Hard To Create A Case For Income Investors, Who Seek Covered-Call Exposure"", ""summary"": ""We critique investing in DIVO due to lack of strategic rationale, compares to other covered call names JEPQ, FEPI, JEPI. Read an analysis of DIVO ETF here.""}, {""date"": ""20250124130604"", ""headline"": ""Amgen : Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products"", ""summary"": ""Amgen Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to...""}, {""date"": ""20250124141805"", ""headline"": ""Amgen : North Carolina Ribbon Cutting Marks Important Milestone in Expansion to Meet Growing Demand for Amgen Medicines"", ""summary"": ""Amgen opened its newest cutting-edge drug substance facility in Holly Springs, North Carolina, with a ribbon cutting ceremony on January 24. The event took place less than two months after the biotech...""}, {""date"": ""20250124161706"", ""headline"": ""Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms"", ""summary"": ""Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms""}, {""date"": ""20250125080000"", ""headline"": ""5 Best CEFs This Month For Nearly 10% Yield (January 2025)"", ""summary"": ""Discover high-yield closed-end funds for income investors with reasonable total returns. Click for our process of winnowing out the best CEFS this month.""}]",{}
12,2025-01-26,273.2127380371094,2025-02-02,283.132568359375,0.03630808136375485,U4,"[{""date"": ""20250127163600"", ""headline"": ""Amgen Inc. stock underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""Amgen Inc. stock underperforms Monday when compared to competitors despite daily gains""}, {""date"": ""20250128112744"", ""headline"": ""Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business"", ""summary"": """"}, {""date"": ""20250128150000"", ""headline"": ""Drugmakers Show Restraint on Price Increases in New Trump Era"", ""summary"": ""Drugmakers Show Restraint on Price Increases in New Trump Era""}, {""date"": ""20250130070806"", ""headline"": ""Correction And Interpretation Of Errors In A Patent At The UPC"", ""summary"": ""In a recent decision, the UPC Court of Appeal ruled on the correction of errors in a patent by interpretation. This case, concerning Alexion Pharmaceuticals' patent , underscores the importance of...""}, {""date"": ""20250130170315"", ""headline"": ""Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)"", ""summary"": ""Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising earnings outlook.""}, {""date"": ""20250131105000"", ""headline"": ""AbbVie Stock Jumps on Earnings and Revenue Beat"", ""summary"": ""AbbVie Stock Jumps on Earnings and Revenue Beat""}, {""date"": ""20250201110000"", ""headline"": ""Busy Earnings Season Continues With Alphabet, Disney, Palantir To Report Results"", ""summary"": ""Tech biggies continue to report earnings this week. A bunch of labor reports are to be released. EU inflation data will be released on Wednesday. See more here.""}, {""date"": ""20250202060956"", ""headline"": ""Wall Street Week Ahead"", ""summary"": ""Stay informed with the latest financial updates! Get a daily podcast of Wall Street Breakfast on Seeking Alpha, iTunes, and Spotify by 8:00 a.m.""}]",{}
13,2025-02-02,283.132568359375,2025-02-09,291.1875,0.028449329186323036,U3,"[{""date"": ""20250202060956"", ""headline"": ""Wall Street Week Ahead"", ""summary"": ""Stay informed with the latest financial updates! Get a daily podcast of Wall Street Breakfast on Seeking Alpha, iTunes, and Spotify by 8:00 a.m.""}, {""date"": ""20250203090417"", ""headline"": ""AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS"", ""summary"": ""THOUSAND OAKS - Amgen today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after the close of the U.S. financial markets.The...""}, {""date"": ""20250203163500"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Amgen Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20250204055510"", ""headline"": ""Alphabet results lead busy day of earnings"", ""summary"": ""Alphabet results lead busy day of earnings""}, {""date"": ""20250204161400"", ""headline"": ""Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains"", ""summary"": ""Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains""}, {""date"": ""20250204203232"", ""headline"": ""Amgen, Inc. (AMGN) Q4 2024 Earnings Call Transcript"", ""summary"": ""Amgen, Inc. (NASDAQ:AMGN) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway - Chairman,...""}, {""date"": ""20250204203334"", ""headline"": ""Amgen Inc. 2024 Q4 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Amgen Inc.""}, {""date"": ""20250205032416"", ""headline"": ""Amgen: EPS up 13% in Q4"", ""summary"": ""Amgen reported adjusted EPS for the last three months of 2024 up 13% to $5.31, with non-GAAP operating margin down 0.4 points to 46.3% but revenues up 11% to $9.1 billion.Product sales were up 11%,...""}, {""date"": ""20250205100441"", ""headline"": ""Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs"", ""summary"": ""Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs""}, {""date"": ""20250205115200"", ""headline"": ""Amgen, NVIDIA Corp. share gains contribute to Dow's nearly 150-point climb"", ""summary"": ""Amgen, NVIDIA Corp. share gains contribute to Dow's nearly 150-point climb""}, {""date"": ""20250205131030"", ""headline"": ""Regeneron Is Playing Defense With Capital Allocation"", ""summary"": ""Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read why I rate REGN a Buy.""}, {""date"": ""20250205140800"", ""headline"": ""Dow up 264 points on gains for Amgen, NVIDIA Corp. shares"", ""summary"": ""Dow up 264 points on gains for Amgen, NVIDIA Corp. shares""}, {""date"": ""20250205150845"", ""headline"": ""Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating"", ""summary"": ""Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read why AMGN stock is a Buy.""}, {""date"": ""20250206073712"", ""headline"": ""Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)"", ""summary"": ""Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.""}, {""date"": ""20250206121200"", ""headline"": ""Dow's nearly 175-point fall led by losses in Honeywell, Salesforce shares"", ""summary"": ""Dow's nearly 175-point fall led by losses in Honeywell, Salesforce shares""}, {""date"": ""20250206143200"", ""headline"": ""Dow's nearly 300-point drop led by losses for Honeywell, Salesforce shares"", ""summary"": ""Dow's nearly 300-point drop led by losses for Honeywell, Salesforce shares""}, {""date"": ""20250206153935"", ""headline"": ""Amgen: The Charts Didn't Lie, Upgrade To Buy"", ""summary"": ""Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance. Click to read why AMGN is a Buy.""}, {""date"": ""20250206154700"", ""headline"": ""Dow's 175-point fall led by losses in shares of Honeywell, Salesforce"", ""summary"": ""Dow's 175-point fall led by losses in shares of Honeywell, Salesforce""}, {""date"": ""20250206161700"", ""headline"": ""Amgen Stock Has Surged. Here\u2019s Where It\u2019s Headed Next."", ""summary"": ""Amgen Stock Has Surged. Here\u2019s Where It\u2019s Headed Next.""}, {""date"": ""20250207041119"", ""headline"": ""Amgen: Multiple Strengths, But The Valuation Is A Concern"", ""summary"": """"}, {""date"": ""20250207101844"", ""headline"": ""23 Upcoming Dividend Increases, Including 2 Kings"", ""summary"": ""Discover the latest dividend hikes for 23 companies, including dividend kings SJW Group and California Water Service Group, with 5% and 7.1% increases. Explore more details here.""}, {""date"": ""20250207123000"", ""headline"": ""AI Earnings, Tariff Threats, And Other Bellwether Stocks"", ""summary"": ""Palantir's soaring but concerns remain. Tariff threats and bellwether earnings.""}, {""date"": ""20250207163500"", ""headline"": ""Amgen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20250208020015"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of February 9"", ""summary"": ""Stay informed on the latest dividend activity for top companies with this weekly summary. Read more here.""}, {""date"": ""20250208044416"", ""headline"": ""Terns Pharma: I Don't See The Positioning"", ""summary"": ""Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.""}, {""date"": ""20250208075421"", ""headline"": ""One 'Safer' Buy In 10 February Dogs Of The Dow"", ""summary"": ""Verizon's dividend yield and Merck\u00e2\u0080\u0099s growth lead the Dow Dogs. Read why they\u00e2\u0080\u0099re set for solid returns, with other top picks closely following in February 2026.""}, {""date"": ""20250208081500"", ""headline"": ""Funds Only SWAN Retirement Portfolio: $6,000 Monthly Income"", ""summary"": """"}]",{}
14,2025-02-09,291.1875,2025-02-16,291.1600036621094,-9.442829067396463e-05,D1,"[{""date"": ""20250210042247"", ""headline"": ""Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns"", ""summary"": ""Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a great buy on dips if they happen.""}, {""date"": ""20250210163647"", ""headline"": ""Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming"", ""summary"": ""Explore the potential of Ideaya Biosciences, Inc.'s Darovasertib in treating uveal melanoma as a monotherapy and in combination therapy. Click for more on IDYA.""}, {""date"": ""20250211014000"", ""headline"": ""Steady M&A Deals To Begin 2025, Disappointing IPOs So Far"", ""summary"": ""A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.""}, {""date"": ""20250211152212"", ""headline"": ""Mereo BioPharma: Good Science, Fairly Valued"", ""summary"": ""Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.""}, {""date"": ""20250212152204"", ""headline"": ""Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript"", ""summary"": ""Amgen, Inc. (NASDAQ:AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ETCompany ParticipantsNarimon...""}, {""date"": ""20250212162606"", ""headline"": ""IGA: Good Diversification And Fully-Covered Distribution (Rating Upgrade)"", ""summary"": ""Voya Global Advantage and Premium Opportunity Fund has a 10.74% yield, diversification benefits, and well-covered distributions. Click for my IGA CEF update.""}, {""date"": ""20250212204000"", ""headline"": ""Janus Henderson Global Life Sciences Fund Q4 2024 Commentary"", ""summary"": ""The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary. ""}, {""date"": ""20250213174928"", ""headline"": ""Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain"", ""summary"": ""Kiniksa Pharmaceuticals stock is attractive because it trades near 52-week lows, and its marketed drug gains traction. Click to find out why KNSA is a Hold.""}, {""date"": ""20250213205800"", ""headline"": ""Janus Henderson Global Life Sciences Diversified ADR Managed Account Q4 2024 Commentary"", ""summary"": ""The Portfolio returned -10.75% (gross) and the MSCI World Health Care IndexSM returned -11.32%. Read more here.""}, {""date"": ""20250214163500"", ""headline"": ""Amgen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Friday when compared to competitors""}, {""date"": ""20250214170856"", ""headline"": ""SCHD Is So Boring, And Big Changes Are In Store"", ""summary"": ""The Schwab U.S. Dividend Equity ETF is a top pick for conservative investors seeking stable returns & dividend growth. Click here to read why SCHD ETF is a Buy.""}, {""date"": ""20250216215403"", ""headline"": ""Why Regeneron's Price May Soon Break Out"", ""summary"": ""Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.""}]",{}
15,2025-02-16,291.1600036621094,2025-02-23,303.010009765625,0.04069929232885827,U5,"[{""date"": ""20250216215403"", ""headline"": ""Why Regeneron's Price May Soon Break Out"", ""summary"": ""Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.""}, {""date"": ""20250218091901"", ""headline"": ""Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib"", ""summary"": """"}, {""date"": ""20250219031000"", ""headline"": ""Aristotle Global Equity Q4 2024 Commentary"", ""summary"": ""For Q4 2024, Aristotle Capital\u00e2\u0080\u0099s Global Equity Composite posted a total return of -7.72% gross of fees (-7.80% net of fees). Click here to read more.""}, {""date"": ""20250219224604"", ""headline"": ""Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript)"", ""summary"": ""Amgen, Inc. (NASDAQ:AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference Call February 19, 2025 3:00 PM ETCompany ParticipantsJean-Charles Soria...""}, {""date"": ""20250221163600"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Amgen Inc. stock outperforms competitors on strong trading day""}]",{}
16,2025-02-23,303.010009765625,2025-03-02,308.05999755859375,0.016666075806785585,U2,"[{""date"": ""20250224012826"", ""headline"": ""Amgen plans $200 million investment in India site, CEO says"", ""summary"": ""U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert A. Bradway said at the...""}, {""date"": ""20250224083500"", ""headline"": ""Columbia Flexible Capital Income Fund Q4 2024 Commentary"", ""summary"": ""Columbia Flexible Capital Income Fund Institutional Class shares returned -0.67% in Q4 2024. Click here to read the full commentary. ""}, {""date"": ""20250224112000"", ""headline"": ""Nike, Travelers share gains contribute to Dow's nearly 125-point climb"", ""summary"": ""Nike, Travelers share gains contribute to Dow's nearly 125-point climb""}, {""date"": ""20250224124500"", ""headline"": ""Dow's nearly 250-point rally highlighted by gains in shares of Nike, Travelers"", ""summary"": ""Dow's nearly 250-point rally highlighted by gains in shares of Nike, Travelers""}, {""date"": ""20250224152800"", ""headline"": ""Nike, Travelers share gains contribute to Dow's 131-point climb"", ""summary"": ""Nike, Travelers share gains contribute to Dow's 131-point climb""}, {""date"": ""20250225090000"", ""headline"": ""10 Undervalued Dividend Growth Stocks: February 2025"", ""summary"": """"}, {""date"": ""20250225124300"", ""headline"": ""Home Depot, Walmart share gains contribute to Dow's 118-point climb"", ""summary"": ""Home Depot, Walmart share gains contribute to Dow's 118-point climb""}, {""date"": ""20250225152000"", ""headline"": ""Walmart, Home Depot share gains contribute to Dow's 236-point climb"", ""summary"": ""Walmart, Home Depot share gains contribute to Dow's 236-point climb""}, {""date"": ""20250226123150"", ""headline"": ""Amgen Stock: Why I Still Rate It A 'Buy'"", ""summary"": ""In early February, Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' rating.""}, {""date"": ""20250226125600"", ""headline"": ""Dow falls 110 points on losses for Boeing, Amgen shares"", ""summary"": ""Dow falls 110 points on losses for Boeing, Amgen shares""}, {""date"": ""20250226135700"", ""headline"": ""Boeing, Apple share losses lead Dow's 289-point drop"", ""summary"": ""Boeing, Apple share losses lead Dow's 289-point drop""}, {""date"": ""20250226151300"", ""headline"": ""Apple, Amgen share losses lead Dow's 175-point drop"", ""summary"": ""Apple, Amgen share losses lead Dow's 175-point drop""}, {""date"": ""20250228070000"", ""headline"": ""Drug Stocks Are the New Safe Bet in a Shaky Market"", ""summary"": ""Drug Stocks Are the New Safe Bet in a Shaky Market""}, {""date"": ""20250228160204"", ""headline"": ""AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE"", ""summary"": ""THOUSAND OAKS, Calif., Feb. 28, 2025 /PRNewswire/ --\u00a0Amgen will present at the 45th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday, March 5, 2025. Jay Bradner, executive vice...""}, {""date"": ""20250301002148"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of March 2"", ""summary"": ""Read here for key dividend updates for Dividend Champions, Contenders, and Challengers. Learn about changes, ex-dividend dates, & payment schedules.""}, {""date"": ""20250302031813"", ""headline"": ""AstraZeneca, Amgen drug shows positive results in nasal polyps trials"", ""summary"": ""An asthma drug has shown positive results when used to treat nasal polyps, researchers have said.Tezepelumab was first approved for treating asthma in 2021, but new research led by a University of...""}]",{}
17,2025-03-02,308.05999755859375,2025-03-09,324.8599853515625,0.05453479168379638,U5+,"[{""date"": ""20250302031813"", ""headline"": ""AstraZeneca, Amgen drug shows positive results in nasal polyps trials"", ""summary"": ""An asthma drug has shown positive results when used to treat nasal polyps, researchers have said.Tezepelumab was first approved for treating asthma in 2021, but new research led by a University of...""}, {""date"": ""20250303105921"", ""headline"": ""AMGEN - POSITIVE RESULTS FROM TEZSPIRE PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS"", ""summary"": ""THOUSAND OAKS - Amgen and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE significantly reduced nasal polyp severity, the need...""}, {""date"": ""20250304145603"", ""headline"": ""Dogs Of The Dow Chase A \""Safer\"" Buy For March"", ""summary"": ""My monthly update and commentary on the top dividend stock picks from the Dogs Of The Dow, March 2025 edition. Click here to read more about Dogs of the Dow.""}, {""date"": ""20250304165605"", ""headline"": ""AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND"", ""summary"": ""THOUSAND OAKS, Calif., March 4, 2025 /PRNewswire/ -- Amgen today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The dividend will be paid on...""}, {""date"": ""20250305110904"", ""headline"": ""Amgen Inc. (AMGN) 45th Annual TD Cowen Health Care Conference (Transcript)"", ""summary"": ""Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive Vice...""}, {""date"": ""20250305133100"", ""headline"": ""5 Big Biopharmaceutical Stocks That Are Finding Favor"", ""summary"": ""5 Big Biopharmaceutical Stocks That Are Finding Favor""}, {""date"": ""20250305153900"", ""headline"": ""Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out"", ""summary"": ""Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out""}, {""date"": ""20250307100000"", ""headline"": ""Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup"", ""summary"": ""Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical trials for its experimental weight-loss drug, MariTide. And Big Pharma is lobbying for a tax break that would have saved it at least $15 billion in 2023.""}, {""date"": ""20250307100300"", ""headline"": ""2 Dividend Stocks to Buy for a Lifetime of Passive Income"", ""summary"": ""Dividend investors don't buy shares of companies hoping they will suspend their payouts soon.  The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else being equal.  Let's discuss two that have what it takes to pay investors regular dividends for good: Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).""}, {""date"": ""20250307120000"", ""headline"": ""Recession Risk And Pockets Of Strength"", ""summary"": ""Budweiser keeps pushing higher. AI segments moving down. Bitcoin in short and long-term. Economy not looking as sweet.""}, {""date"": ""20250307133800"", ""headline"": ""Dow's 114-point rally highlighted by gains in IBM, Verizon shares"", ""summary"": ""Dow's 114-point rally highlighted by gains in IBM, Verizon shares""}, {""date"": ""20250307143900"", ""headline"": ""IBM, Verizon share gains lead Dow's 250-point jump"", ""summary"": ""IBM, Verizon share gains lead Dow's 250-point jump""}, {""date"": ""20250307154300"", ""headline"": ""Dow's nearly 150-point rally led by gains in IBM, Verizon stocks"", ""summary"": ""Dow's nearly 150-point rally led by gains in IBM, Verizon stocks""}, {""date"": ""20250307163102"", ""headline"": ""Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound?"", ""summary"": ""Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20250308110000"", ""headline"": ""AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS"", ""summary"": ""Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis (AD).""}, {""date"": ""20250308110000"", ""headline"": ""A Major Market Rotation Is Likely Coming"", ""summary"": ""The market hasn\u00e2\u0080\u0099t priced in several undervalued AI stocks. Read why these stocks could outperform tech in the next market cycle.""}, {""date"": ""20250308154100"", ""headline"": ""3 Magnificent Growth Stocks to Buy in March"", ""summary"": ""Prosper Junior Bakiny (Eli Lilly): What's considered excellent revenue growth depends on the industry.  With that context in mind, consider that Eli Lilly's revenue growth has not dipped below 20% since mid-2023.""}]",{}
18,2025-03-09,324.8599853515625,2025-03-16,313.7099914550781,-0.03432246013438034,D4,"[{""date"": ""20250310103500"", ""headline"": ""Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus"", ""summary"": ""Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.""}, {""date"": ""20250310113032"", ""headline"": ""Amgen and Kyowa Kirin\u2019s rocatinlimab trial for atopic dermatitis meets endpoints"", ""summary"": ""All the key secondary endpoints of the trial were met, demonstrating the \u201cstatistical significance\u201d of the therapy.""}, {""date"": ""20250310123917"", ""headline"": ""AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS"", ""summary"": ""THOUSAND OAKS, TOKYO - Amgen and Kyowa Kirin Co., Ltd. today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell...""}, {""date"": ""20250310132700"", ""headline"": ""AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies"", ""summary"": ""Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.""}, {""date"": ""20250310154204"", ""headline"": ""Amgen : Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products"", ""summary"": ""Amgen Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to...""}, {""date"": ""20250310164640"", ""headline"": ""Amgen: Riding The MariTide Of Monthly Weight Loss"", ""summary"": ""Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.""}, {""date"": ""20250310181712"", ""headline"": ""Stock market sell-off: Why these stocks are in the green amid the pain"", ""summary"": ""The shift to defense is on.""}, {""date"": ""20250311040810"", ""headline"": ""Amgen Files Three IPR Petitions Challenging Bristol-Myers Squibb Anti-PD1 And Anti-CTLA-4 Antibody Combination Method Of Treatment Patents"", ""summary"": ""On February 28, Amgen, Inc. filed three petitions for inter partes review, challenging the validity of all claims in three patents assigned to Bristol-Myers Squibb Co. . The claims of all three...""}, {""date"": ""20250311130205"", ""headline"": ""BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund"", ""summary"": ""BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.""}, {""date"": ""20250311134000"", ""headline"": ""These 10 stocks beating the market\u2019s recent Trump slump have this in common"", ""summary"": ""These 10 stocks beating the market\u2019s recent Trump slump have this in common""}, {""date"": ""20250311154008"", ""headline"": ""HALO vs. AMGN: Which Stock Is the Better Value Option?"", ""summary"": ""HALO vs. AMGN: Which Stock Is the Better Value Option?""}, {""date"": ""20250312095600"", ""headline"": ""Verizon, Amgen share losses lead Dow's nearly 150-point fall"", ""summary"": ""Verizon, Amgen share losses lead Dow's nearly 150-point fall""}, {""date"": ""20250312100642"", ""headline"": ""Dow's relief rally quickly fades. Here are some key stocks dragging it down."", ""summary"": ""Dow's relief rally quickly fades. Here are some key stocks dragging it down.""}, {""date"": ""20250312105700"", ""headline"": ""Verizon, McDonald's share losses lead Dow's 313-point drop"", ""summary"": ""Verizon, McDonald's share losses lead Dow's 313-point drop""}, {""date"": ""20250312140443"", ""headline"": ""Amgen Inc. (AMGN): Among Dobermans of the Dow to Buy"", ""summary"": ""We recently published a list of Dobermans of the Dow: 10 Stocks to Consider. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an alternative to the well-known Dogs of the Dow [\u2026]""}, {""date"": ""20250313105222"", ""headline"": ""Uplizna Significantly Improves Generalized Myasthenia Gravis Symptoms In Acetylcholine Receptor Autoantibody-Positive Patients Over 52 Weeks"", ""summary"": ""Amgen Inc: * UPLIZNA\u00ae SIGNIFICANTLY IMPROVESGENERALIZEDMYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTORAUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS * AMGEN INC: NO...""}, {""date"": ""20250313130000"", ""headline"": ""UPLIZNA\u00ae (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA\u00ae (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG). The results demonstrated durable and sustained efficacy of UPLIZNA in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG with two doses a year, following an initial loading dose. Findings will be presented as a late-breaking oral presentation during the American Ac""}, {""date"": ""20250313135007"", ""headline"": ""Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick"", ""summary"": ""Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.""}, {""date"": ""20250313135823"", ""headline"": ""Amgen Says Phase 3 Data Support Uplizna's Efficacy in Generalized Myasthenia Gravis"", ""summary"": ""Amgen (AMGN) said Thursday said that a phase 3 trial of its Uplizna drug showed \""durable and sustain""}, {""date"": ""20250313153029"", ""headline"": ""Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?"", ""summary"": ""Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20250313153626"", ""headline"": ""Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year"", ""summary"": ""On Thursday, Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with generalized myasthenia gravis (gMG), a chronic autoimmune disease that causes muscle weakness. It affects the muscles used for breathing, swallowing, facial expressions, and movement. The results demonstrated the durable and sustained efficacy of Uplizna in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG with two doses a year following""}, {""date"": ""20250313160919"", ""headline"": ""Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy According to Hedge Funds?"", ""summary"": ""We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in the [\u2026]""}, {""date"": ""20250313172119"", ""headline"": ""Amgen (NasdaqGS:AMGN) Announces Promising MINT Trial Data For UPLIZNA In Generalized Myasthenia Gravis"", ""summary"": ""Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating generalized myasthenia gravis, likely influencing its 14% price increase over the last quarter. These findings, emphasizing the drug's efficacy, coincide with Amgen's Q4 2024 earnings report, which showed a rise in revenue yet a decline in net income, reflecting a mixed financial performance. Despite the broader stock market experiencing declines, with the S&P 500 and...""}, {""date"": ""20250313173106"", ""headline"": ""Amgen\u2019s gMG therapy cuts disease symptoms at one-year mark"", ""summary"": ""Results from the company\u2019s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom impact.""}, {""date"": ""20250314094028"", ""headline"": ""Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?"", ""summary"": ""Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.""}, {""date"": ""20250314110022"", ""headline"": ""AMGEN - UPLIZNA SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS"", ""summary"": ""THOUSAND OAKS - Amgen today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA in adults living with generalized myasthenia gravis .The...""}, {""date"": ""20250314161514"", ""headline"": ""Amgen data \u2018muddies\u2019 outlook for Cartesian, says Oppenheimer"", ""summary"": ""Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company\u2019s Q4 report. The company\u2019s Phase 3 trial in myasthenia gravis remains on track to start by mid-year, the analyst tells investors in a research note. The firm thinks the trial has a \u201cdecent chance at working,\u201d but does not currently view Descartes-08 as a commercially viable therapy. Just today, Amgen (AMGN) announced updated Uplizna results showing a deepening of responses six mo""}, {""date"": ""20250314175651"", ""headline"": ""CMS Announces Manufacturer Participation in Second Cycle of Medicare Drug Price Negotiation"", ""summary"": ""March 14 - * CMS: DEALS SIGNED WITH MANUFACTURERS OF 15 DRUGS COVEREDUNDERMEDICARE PART D SELECTED FOR SECOND CYCLE OF MEDICARE DRUG PRICENEGOTIATION PROGRAM ...""}, {""date"": ""20250316134003"", ""headline"": ""Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'"", ""summary"": ""Discover why Johnson & Johnson and Kenvue offer resilient defensive stocks with high dividends.""}]",{}
19,2025-03-16,313.7099914550781,2025-03-23,316.0400085449219,0.0074272963989334695,U1,"[{""date"": ""20250316134003"", ""headline"": ""Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'"", ""summary"": ""Discover why Johnson & Johnson and Kenvue offer resilient defensive stocks with high dividends.""}, {""date"": ""20250317085448"", ""headline"": ""OPKO and Entera partner to develop obesity pill"", ""summary"": ""OPKO Health and Entera Bioare partnering to develop a once-daily pill forpatients with obesity and other disorders, the companies said onMonday. WHY IT'S IMPORTANT ...""}, {""date"": ""20250317130008"", ""headline"": ""Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""20250317160500"", ""headline"": ""AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study"", ""summary"": ""New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.""}, {""date"": ""20250317163400"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Amgen Inc. stock outperforms competitors on strong trading day""}, {""date"": ""20250317220014"", ""headline"": ""Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider"", ""summary"": ""The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.""}, {""date"": ""20250317225823"", ""headline"": ""Why Organon Is A Top Pick For Income Investors"", ""summary"": ""In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.""}, {""date"": ""20250318093429"", ""headline"": ""Amgen Inc. (AMGN): Among the Best Biotech Stocks to Buy According to Billionaires"", ""summary"": ""We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best biotech stocks. Although biotech stocks had a \u201cchallenging\u201d year in 2024, JPMorgan believes that some of the industry\u2019s companies could [\u2026]""}, {""date"": ""20250318124000"", ""headline"": ""Dividend Income: Lanny's February 2025 Summary"", ""summary"": """"}, {""date"": ""20250318135300"", ""headline"": ""Prediction: These 2 Stocks Will Outperform the Market Through 2030"", ""summary"": ""The more we extend our horizon, the more likely it is that stocks will provide juicy returns.  Leading drugmaker Amgen could have several growth drivers through the end of the decade.  Tepezza remains the only treatment for TED approved in the U.S., and Amgen has also been launching it in other countries.""}, {""date"": ""20250318154900"", ""headline"": ""Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?"", ""summary"": ""AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.""}, {""date"": ""20250318215016"", ""headline"": ""Why the Market Dipped But Amgen (AMGN) Gained Today"", ""summary"": ""Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.""}, {""date"": ""20250319151300"", ""headline"": ""FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review"", ""summary"": ""Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.""}, {""date"": ""20250319163933"", ""headline"": ""Stock Market Today: Nasdaq Jumps On Subtle Fed Policy Shift; Dow Up 383 Points, Aims To Retake Key Chart Level (Live Coverage)"", ""summary"": ""Stock Market Today: Nasdaq Jumps On Subtle Fed Policy Shift; Dow Up 383 Points, Aims To Retake Key Chart Level (Live Coverage)""}, {""date"": ""20250321072147"", ""headline"": ""Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy"", ""summary"": ""Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.""}, {""date"": ""20250321133052"", ""headline"": ""3 of Goldman Sachs' best investing tips for currently volatile markets"", ""summary"": ""Volatile times in markets require precision, Goldman Sachs reminds investors.""}, {""date"": ""20250321141006"", ""headline"": ""Why Amgen (AMGN) is a Top Value Stock for the Long-Term"", ""summary"": ""Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.""}, {""date"": ""20250321171629"", ""headline"": ""Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth"", ""summary"": ""Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic partnerships positioning it as a 2025 Buy.""}, {""date"": ""20250323174716"", ""headline"": ""Is Amgen Inc. (AMGN) The Best Healthcare Dividend Stock to Invest in?"", ""summary"": ""We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best healthcare dividend stocks to invest in. The US healthcare sector has been at the forefront since the emergence of COVID-19 in 2020, [\u2026]""}]",{}
20,2025-03-23,316.0400085449219,2025-03-30,306.95001220703125,-0.02876216963713496,D3,"[{""date"": ""20250323174716"", ""headline"": ""Is Amgen Inc. (AMGN) The Best Healthcare Dividend Stock to Invest in?"", ""summary"": ""We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best healthcare dividend stocks to invest in. The US healthcare sector has been at the forefront since the emergence of COVID-19 in 2020, [\u2026]""}, {""date"": ""20250324215014"", ""headline"": ""Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note"", ""summary"": ""In the latest trading session, Amgen (AMGN) closed at $314.38, marking a -0.53% move from the previous day.""}, {""date"": ""20250325141456"", ""headline"": ""S&P 500 struggles to extend its relief rally. Here are the stocks capping market upside."", ""summary"": ""S&P 500 struggles to extend its relief rally. Here are the stocks capping market upside.""}, {""date"": ""20250325163500"", ""headline"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors""}, {""date"": ""20250326154500"", ""headline"": ""As Vaccine Skepticism Mounts, Moderna\u2019s Business Grows More Precarious"", ""summary"": ""As Vaccine Skepticism Mounts, Moderna\u2019s Business Grows More Precarious""}, {""date"": ""20250327072744"", ""headline"": ""How AZ and Amgen\u2019s Tezspire respiratory data ups the \u2018level of ambition\u2019 in immunology"", ""summary"": ""After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.""}, {""date"": ""20250327073000"", ""headline"": ""Franklin Biotechnology Discovery Fund Q4 2024 Commentary"", ""summary"": """"}, {""date"": ""20250327123100"", ""headline"": ""VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug"", ""summary"": ""Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.""}, {""date"": ""20250327142200"", ""headline"": ""Trump Weighs Tariffs on Pharma in Ireland. What It Means for Amgen, Gilead."", ""summary"": ""Jefferies analysts singled out the stocks that will be affected the most and the least by potential import taxes.""}, {""date"": ""20250328123000"", ""headline"": ""Which Dow Jones Stock Is Cheaper, Amgen or Merck?"", ""summary"": ""Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an impressive 21% year to date.  Meanwhile, shares of its pharmaceutical rival Merck (NYSE: MRK) have lagged, down 8% in the same period.  Amgen shareholders are celebrating, but have you wondered which stock is cheaper right now?""}, {""date"": ""20250328130008"", ""headline"": ""Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""20250328130117"", ""headline"": ""2 Large-Cap Stocks with Solid Fundamentals and 1 to Turn Down"", ""summary"": ""Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they\u2019ve already captured significant portions of their markets.""}, {""date"": ""20250328141500"", ""headline"": ""2 Surefire Dividend Stocks That Could Pay You for Life"", ""summary"": ""Dividend investing is an excellent strategy for (at least) two reasons.  Here are two companies that can pull it off: Amgen (NASDAQ: AMGN) and Coca-Cola (NYSE: KO).  Amgen paid its first dividend in 2011.""}, {""date"": ""20250330035000"", ""headline"": ""abrdn Healthcare Investors Q4 2024 Commentary"", ""summary"": ""The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.""}, {""date"": ""20250330045000"", ""headline"": ""abrdn Life Sciences Investors Q4 2024 Commentary"", ""summary"": ""The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.""}]",{}
